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ABSTRACT
Ischemic heart disease is the leading cause of death globally, even though the
prognosis of the disease has improved with advancing treatments. One particular
phenomenon which could be treated more effectively is ischemia-reperfusion injury. 
While reperfusion, the return of blood flow to the heart after infarction, is necessary
for the functionality of the heart, it is a stress itself and contributes to the myocardial
damage. Ischemia-reperfusion injury could be prevented pharmacologically, and 
novel targets for this are needed.
Heart failure is a life-threatening disorder with high death rates within years from
its diagnosis. In addition to acquired causes, there is a strong heritable component to
its risk. Only a few of genetic variants attributing to the risk are well characterized.
This thesis aimed to identify novel therapeutic targets for ischemic heart disease,
especially ischemia-reperfusion injury, and genetic markers associated with risk of
heart failure. Large-scale screenings on cell and tissue samples, as well as genome-
wide screening on human genetic data from the FINRISK study cohort, were carried
out. First, the family of receptor tyrosine kinases (RTK), a family of cell surface
receptors involved in cellular survival and proliferation, was assessed in the context
of ischemia-reperfusion injury. A member of the family, ROR1, was detected as a
potential candidate for therapeutic targeting. In the second study, an unbiased screen
exploiting a combination of drug and shRNA libraries identified another member of
RTK family, EGFR, as a putative therapeutic target for ischemia-reperfusion. 
Gefitinib, an EGFR tyrosine kinase inhibitor clinically used as a cancer drug, was
identified as a candidate for drug repurposing. The genetic association study on the
FINRISK population identified an E140K variant of the TRIM55 gene to be
associated with heart failure. TRIM55 E140K was also shown to negatively affect
cardiomyocyte-specific functions in vitro and in vivo.
Altogether, the findings demonstrate that novel candidates for therapeutic targets
and genetic markers for cardiac disorders can be effectively identified by preclinical
and genetic screening methods. ROR1 and EGFR were identified as potential targets
for treatment of ischemia-reperfusion injury, and TRIM55 E140K as a genetic
marker potentially modifying the risk for heart failure.
KEYWORDS: genetics, heart failure, high-throughput screening, ischemia-
reperfusion injury, myocardial infarction
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TIIVISTELMÄ
Iskeeminen sydänsairaus on maailmanlaajuisesti yleisin kuolinsyy. Vaikka taudin
hoidossa on edistytty, siihen liittyy yhä merkittävää sairastavuutta ja kuolleisuutta.
Iskemia-reperfuusiovaurio on tautiin liittyvä alihoidettu ilmiö. Reperfuusio eli
verenkierron palautuminen sydämeen infarktin jälkeen on tarpeellista sydämen
toimintakyvyn palautumiselle, mutta se on itsessään stressitekijä, joka tekee lisänsä
sydänlihasvaurioon. Vauriota voidaan estää lääkehoitojen avulla, ja uusien 
lääkevaikutuskohteiden tunnistaminen tähän tarkoitukseen on tarpeen.
Sydämen vajaatoiminta on hengenvaarallinen sairaus, joka johtaa usein
kuolemaan jo muutamassa vuodessa. Hankinnaisten syiden lisäksi perinnölliset
tekijät vaikuttavat vahvasti sen riskiin. Kuitenkin vain kourallinen riskiä lisääviä 
geneettisiä variantteja on kuvattu tarkasti.
Tämän väitöskirjan tavoitteena oli tunnistaa uusia lääkevaikutuskohteita
iskeemisen sydänsairauden, etenkin iskemia-reperfuusiovaurion, hoitoon, ja
sydämen vajaatoiminnan riskiin liittyviä geneettisiä tekijöitä. Työssä hyödynnettiin 
seulontoja solu- ja kudosnäytteillä ja toteutettiin genominlaajuinen seulonta
FINRISKI-tutkimuksen geenidatasta. Seuloimme iskemia-reperfuusiovaurioon 
liittyen reseptorityrosiinikinaasien (RTK) perhettä. RTK-perhe koostuu solunpinnan
reseptoreista, jotka säätelevät solujen selviytymistä ja jakautumista. Perheen jäsen
ROR1 tunnistettiin lupaavana vaurion hoitokohteena. Toisessa osatyössä 
tunnistettiin lääkeaine- ja shRNA-kirjastoja hyödyntävän seulonnan avulla toinen
RTK-perheen jäsen, EGFR, mahdollisena lääkehoitokohteena. EGFR:ää estävä 
syöpälääke, tyrosiinikinaasi-inhibiittori gefitinibi, tunnistettiin potentiaalisena
lääkkeenä, joka voidaan uudelleenkohdistaa iskemia-reperfuusiovaurion hoitoon.
FINRISKI-aineiston geneettisessä assosiaatiotutkimuksessa havaittiin TRIM55-
geenin E140K-variantin liittyvän sydämen vajaatoiminnan riskiin. Variantin
osoitettiin vaikuttavan negatiivisesti sydänsolujen toimintaan in vivo ja in vitro.
Uusia lääkehoitokohteita ja geenitekijöitä voidaan tehokkaasti löytää
prekliinisten ja geneettisten seulontametodien avulla. ROR1 ja EGFR tunnistettiin
lupaavina iskemia-reperfuusiovaurion lääkehoitokohteina, ja TRIM55 E140K
sydämen vajaatoiminnan riskiin vaikuttavana geneettisenä tekijänä.
AVAINSANAT: genetiikka, iskemia-reperfuusiovaurio, suurten aineistojen
seulonta, sydämen vajaatoiminta, sydäninfarkti
5 
 
  
   
   
    
    
    
    
 
   
  
   
 
   
    
    
     
    
    
    
     
    
    
    
    
    
  
   
  
   
    
    
     
    
   
  
  
   
Table of Contents
Abbreviations .................................................................................. 9
List of Original Publications......................................................... 11
1 Introduction ........................................................................... 12
2 Review of the Literature ....................................................... 13
2.1 Ischemic heart disease .......................................................... 13
2.1.1 Ischemic heart disease is a major cause of death ....... 13
2.1.2 Acute myocardial infarction and ischemia-
reperfusion injury......................................................... 13
2.1.3 Current treatment of ischemic heart disease and
myocardial infarction ................................................... 16
2.1.4 Treatments under development for ischemia-
reperfusion injury......................................................... 16
2.2 Heart failure ........................................................................... 19
2.2.1 Pathophysiology of heart failure .................................. 19
2.2.2 Genetics of heart failure .............................................. 20
2.2.3 Current treatment of heart failure ................................ 22
2.2.4 Treatments under development for heart failure .......... 22
2.3 Receptor tyrosine kinases ...................................................... 23
2.3.1 Structure and activation of receptor tyrosine kinases .. 23
2.3.2 Signaling pathways activated by RTKs........................ 24
2.3.3 Regulated intramembrane proteolysis ......................... 26
2.3.4 ErbB receptor family.................................................... 27
2.3.5 ROR receptors ............................................................ 29
2.3.6 RTKs in cardiac development...................................... 30
2.3.7 RTKs with therapeutic potential in myocardial
ischemia-reperfusion................................................... 31
2.3.8 Regenerative potential of myocardium conferred by
RTKs........................................................................... 33
2.3.9 RTKs implicated in heart failure................................... 34
2.3.10 Cardiotoxicity of RTK inhibitors ................................... 35
2.4 TRIM proteins ........................................................................ 36
2.4.1 Protein control by ubiquitination .................................. 36
2.4.2 TRIM proteins are ubiquitin E3 ligases with various
functions...................................................................... 37
2.4.3 The muscle ring finger family members are central
TRIMs in the heart....................................................... 39
6
 
  
   
    
    
     
    
    
    
      
  
   
    
    
    
     
    
    
      
    
 
   
     
    
    
  
   
     
     
    
    
    
    
     
  
   
  
    
  
    
     
    
    
   
   
   
   
2.4.4 Ubiquitination targets and interaction partners of
MURFs........................................................................ 40
2.4.5 Specific role of TRIM55 in the heart............................. 40
3 Aims ....................................................................................... 42
4 Materials and Methods.......................................................... 43
4.1 Cell culture (I-III)..................................................................... 43
4.1.1 Hypoxia-reoxygenation treatment (I-II) ........................ 43
4.1.2 Transient transfection (III)............................................ 43
4.1.3 Fluorescence-activated cell sorting (FACS) (III)........... 43
4.1.4 Generation of HL-1 cell lines carrying Trim55
variants with CRISPR-Cas9 (III) .................................. 44
4.1.5 Ligands, chemical compounds and inhibitors (I-III) ...... 44
4.2 Expression plasmids (III) ........................................................ 45
4.3 Primary antibodies.................................................................. 46
4.4 Small interfering RNAs (I, III) .................................................. 47
4.5 Cell lysis, immunoprecipitation and Western blotting .............. 47
4.6 Cellular viability assays (I-III) .................................................. 48
4.7 Pig model of myocardial ischemia-reperfusion injury (I).......... 49
4.8 Phospho-RTK array analysis of pig myocardium samples (I).. 50
4.9 RNA extraction, RNA-sequencing and real-time RT-PCR 
(I, III)....................................................................................... 50
4.10 ShRNA library screening on HL-1 cells (II) ............................. 51
4.11 Drug library screening on HL-1 cells (II) ................................. 52
4.12 Cell cycle analysis (III)............................................................ 52
4.13 Immunofluorescence microscopy and analysis of
hypertrophy (III) ...................................................................... 52
4.14 Calcium transient measurements (III) ..................................... 53
4.15 Zebrafish embryo experiments (II, III) ..................................... 53
4.16 Database analyses (I, III)........................................................ 54
4.17 3D modeling of TRIM55 (III) ................................................... 55
4.18 Statistical analyses................................................................. 55
5 Results ................................................................................... 58
5.1 Several RTKs are active and regulated in hypoxic heart (I) .... 58
5.2 ROR1 is downregulated in acutely hypoxic heart and its
knockdown improves cardiomyocyte viability in hypoxia-
reoxygenation (I) .................................................................... 59
5.3 Combined shRNA and drug screening reveals novel
potential targets for ischemia-reperfusion injury (II) ................ 60
5.4 EGFR inhibitor gefitinib preserves cardiac function in 
ischemia-reperfusion injury (II) ............................................... 60
5.5 E140K variant of TRIM55 is linked to risk of heart failure (III) . 61
5.6 TRIM55 E140K affects cardiomyocyte-specific functions (III) . 62
6 Discussion ............................................................................. 64
6.1 Novel therapeutic targets for ischemia-reperfusion are
needed ................................................................................... 64
6.2 Novel therapeutic targets for ischemia-reperfusion can be
identified with preclinical screening approaches ..................... 64
7 
 
   
   
 
  
   
   
  
    
    
   
   
   
  
7
6.3 RTK family members are differentially regulated by
ischemia................................................................................. 65
6.4 ROR1 inhibition is potentially cardioprotective in ischemia-
reperfusion injury.................................................................... 66
6.5 Role of EGFR differs from that of ErbB2 and ErbB4 in the
pathophysiology of ischemia-reperfusion injury ...................... 66
6.6 Functional characterization of the damaging TRIM55 E140K
variant gives insight into its pathological role in heart failure .. 67
Conclusions .......................................................................... 69
Acknowledgements....................................................................... 70
References ..................................................................................... 72
Original Publications..................................................................... 87
8
 
 
   
  
    
  
   
  
  
  
  
   
   
  
  
   
   
 
  
 
  
   
  
  
  
  
  
  
  
  
  
  
  
Abbreviations
ADAM a disintegrin and metalloproteinase
ACE angiotensin-converting enzyme
Akt v-akt murine thymoma viral oncogene homolog
ANP atrial natriuretic peptide
ARB angiotensin receptor blocker
cGMP cyclic guanosine monophosphate
DAG diacylglycerol
DCM dilated cardiomyopathy
ECD extracellular domain
EGF epidermal growth factor
EGFR epidermal growth factor receptor
ErbB v-erb-b avian erythroblastic leukemia viral oncogene homolog
ERK extracellular signal-regulated kinase
FGFR fibroblast growth factor receptor
GRB2 growth factor receptor-bound protein 2
GWAS genome-wide association study 
HB-EGF heparin-binding EGF-like growth factor
HCM hypertrophic cardiomyopathy 
HFpEF heart failure with preserved ejection fraction
HFmrEF heart failure with mid-range ejection fraction
HFrEF heart failure with reduced ejection fraction
ICD intracellular domain
IGF insulin-like growth factor
IP3 inositol trisphosphate
JAK Janus kinase
JM juxtamembrane
MAPK mitogen activated protein kinase
MPTP mitochondrial permeability transition pore
MRA mineralocorticoid receptor antagonist
MURF muscle ring finger
NRG neuregulin
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NO nitric oxide
(N)STEMI (non-)ST-segment elevation myocardial infarction
PDGFR platelet-derived growth factor receptor
PI3K phosphoinositol-3 kinase
PIP2 phosphatidylinositol 4,5-bisphosphate
PIP3 phosphatidylinositol 3,4,5-trisphosphate
PKC protein kinase C
PKG protein kinase G
PLC phospholipase C
PTB phosphotyrosine-binding
RBCC RING-B-Box-coiled-coil
RIP regulated intramembrane proteolysis
RTK receptor tyrosine kinase
RT-PCR reverse transcriptase polymerase chain reaction
TRIM tripartite motif
RISK reperfusion injury salvage kinase
ROR receptor tyrosine kinase-like orphan receptor
SAFE survivor activating factor enhancement
SGLT2 sodium-glucose cotransporter 2
SH2 Src-homology 2 domain
SOS son of sevenless
STAT signal transduced and activator of transcription
TACE tumor-necrosis factor-α converting enzyme
TKI tyrosine kinase inhibitor
TM transmembrane domain
TNF-α tumor necrosis factor alpha
VEGFR vascular endothelial growth factor receptor
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1 Introduction
Ischemic heart disease, or coronary artery disease, and heart failure cause significant
disease burden globally. Diagnostic methods, treatment and prognosis have
improved stably over years but the diseases remain leading killers worldwide. Part
of this is related to poorly characterized genetics and intracellular signaling events
related to the diseases. Better characterization of these factors allows the design of
novel treatments, as well as more efficient ways to diagnose and monitor patients
with the disorders.
Cardiomyocytes are mostly regarded as cells which do not divide after their
maturation. This leads to scarring in the case of myocardial infarction as the lost
cardiomyocytes cannot be efficiently replaced. Therefore, during and after infarction
and the resulting ischemia-reperfusion injury, the cardiomyocyte death should be
maximally prevented. There is considerable, underutilized potential to limit the
ischemia-reperfusion injury and to improve the outcome of the infarction. This thesis
aimed to detect novel treatment targets which could be utilized in this setting.
Genetic factors substantially contribute to the risk of heart failure but the the
underlying variants and their effects on cardiomyocyte signaling are poorly
characterized. Better characterization of these variants improves the knowledge of
intracellular events which lead to heart failure. Therefore, as a part of this thesis
work, a genetic association study of heart failure was performed. A likely functional
variant in TRIM55 was characterized in detail. 
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2 Review of the Literature
2.1 Ischemic heart disease
2.1.1 Ischemic heart disease is a major cause of death
Ischemic heart disease (coronary artery disease, coronary heart disease) is caused by
reduced blood flow to the heart. This is due to accumulation of atherosclerotic plaque
in the coronary arteries (Libby & Theroux 2005). It is the leading cause of death and
disability globally (World Health Organization 2018). Its significance has been
increasing during the last decades also in less developed countries, emphasizing its 
global importance even more (GBD 2017 Causes of Death Collaborators 2018;
World Health Organization 2018). The disease risk is modified by lifestyle factors
such as smoking and diet, concomitant diseases such as diabetes and hypertension, 
as well as genetics. A recent genome-wide association study (GWAS) attributed
21.2% of the heritability of the disease to 304 variants (Nelson et al. 2017) in genes
related e.g. to vascular development, lipid metabolism and inflammation (Nelson et 
al. 2017; Nikpay et al. 2015).
2.1.2 Acute myocardial infarction and ischemia-reperfusion
injury
Acute myocardial infarction is defined as ischemia-related myocardial injury with 
necrosis, evidenced by significant elevation of cardiac troponin values in the plasma, 
together with symptoms consistent with myocardial ischemia (Ibanez et al. 2018;
Thygesen et al. 2019). Most often the infarction is caused by an atherothrombotic
event which means that an atherosclerotic plaque in a coronary artery ruptures and 
the artery gets occluded. Infarction can, however, happen without atherothrombosis,
e.g. due to simple narrowing of the coronary arteries due to atherosclerosis,
vasospasm, coronary dissection or imbalance of oxygen supply and demand alone
(Thygesen et al. 2019). Clinically, different types of infarction are divided to
subcategories of ST-segment elevation myocardial infarction (STEMI) and non-ST-
segment elevation myocardial infarction (NSTEMI), according to 
electrocardiography findings. ST-segment is a specific region in an
13 
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electrocardiogram, denoting the timeframe between the end of the so called QRS
complex, which represents the depolarization of the ventricles, and the start of the T
wave, which represents the repolarization of the ventricles. Changes in the level of
the ST segment signal are observed during ischemia.
Cellular events mediating ischemia-reperfusion injury
Ischemia, resulting in lack of oxygen and nutrients in the myocardium, causes 
myocyte damage in many ways. Oxidative phosphorylation and production of ATP
ceases which stops the contractile function, raises lactate level due to switching to 
anaerobic glycolysis, reduces intracellular pH and eventually raises intracellular
calcium levels (Hausenloy & Yellon 2013). Both cellular necrosis and the
programmed cell death, i.e. apoptosis, have been shown to contribute to the ischemic
myocyte loss (Hausenloy & Yellon 2004; Kajstura et al. 1996).
Reperfusion means the return of blood flow to the heart after infarction. It is an
inevitable goal in order to maintain the functionality of the heart. Reperfusion is, 
however, a stress itself and it exacerbates the injury initiated by ischemia (Hausenloy 
& Yellon 2013; Piper et al. 1998; Yellon & Hausenloy 2007). The consequential
total effect is called ischemia-reperfusion injury. Reversible forms of ischemia-
reperfusion injury are arrhythmias (Hausenloy & Yellon 2013) and myocardial
stunning, a reversible contractile dysfunction (Kloner et al. 1998). Irreversible events
in ischemia-reperfusion injury are microvascular obstruction and lethal myocardial
reperfusion injury which means the reperfusion-induced death of cardiomyocytes
viable at the end of ischemia (Hausenloy & Yellon 2013). 
Lethal myocardial reperfusion injury is due to multiple factors. Oxidative stress
by the restoration of oxygen supply adds to the injury caused by ischemia alone
(Hearse et al. 1973). During ischemia, intracellular calcium concentration increases 
abruptly. Upon the return of oxygen and subsequent re-energization of the
cardiomyocytes, myofibrillar structures start contracting. Due to the concomitant
cytosolic calcium overload, this leads to hypercontracture and mechanical rupture of
the cellular structures (Piper et al. 1998). This damage is potentially enhanced by 
rapid restoration of cellular pH which activates the myofibrillar ATPase (Lemasters
et al. 1996; Piper et al. 1998). Additionally, restoration of pH leads to functional
activation of proteases and phospholipases which is elicited by ischemia (Lemasters 
et al. 1996).
One key factor in the lethal events is the mitochondrial permeability transition
pore (MPTP). It is a non-selective pore protein in the inner membrane of
mitochondria which remains closed during ischemia but opens upon reperfusion due
to mitochondrial calcium overload, oxidative stress and ATP depletion (Griffiths &
Halestrap 1995). Restoration of pH also contributes to MPTP opening (Lemasters et
14
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al. 1996). This leads to mitochondrial membrane depolarization, mitochondrial
swelling, ATP depletion and release of proapoptotic factors to the cytosol (Kim et 
al. 2006). Additional contributing factors to cardiomyocyte damage include
inflammation (Hausenloy & Yellon 2013) and restoration of tissue osmolality which
leads to cellular swelling due to the gradient between intra- and extracellular
osmolality (Inserte et al. 1997; Piper et al. 1998).
A major regulator of cellular responses to hypoxia is the hypoxia-inducible factor
1α (HIF-1α) which is normally quickly degraded and thus present in low quantities
in normoxic cells (Kaelin & Ratcliffe 2008). However, in hypoxia HIF-1α levels are 
quickly increased, and as a transcription factor, it increases the expression of genes
crucial for survival in and adaptation to hypoxia, such as EPO (increasing red blood
cell production), VEGF and ANGPT1 (promoting angiogenesis and vascular
remodeling) (Semenza 2014). HIF-1α has been shown to have protective effects
against cardiac ischemia and pressure-overload heart failure (Semenza 2014).
RISK and SAFE signaling pathways in ischemia-reperfusion injury
Among various intracellular signaling pathways activated upon ischemia-
reperfusion injury, two central cascades have been named as the reperfusion injury
salvage kinase (RISK) pathway and the survivor activating factor enhancement
(SAFE) pathway. RISK pathway includes the phosphatidylinositol-3-OH kinase 
(PI3K)-Akt pathway and the extracellular signal-regulated kinases (ERK1/2)
pathways (Hausenloy & Yellon 2004). Both of these anti-apoptotic signaling 
cascades are activated upon reperfusion and their activation confers cardioprotection
during ischemia-reperfusion injury in preclinical models (Fujio et al. 2000; Matsui
et al. 1999; Shimizu et al. 1998; Yue et al. 2000). Activation of the RISK pathway
leads to prevention of MPTP opening, inhibition of proapoptotic proteins including 
BAD, BAX and BIM and activation of signaling proteins such as protein kinase C
(PKC), endothelial nitric oxide synthase (eNOS) and several transcription factors
(Hausenloy & Yellon 2004).
The SAFE pathway involves the Janus Kinases (JAK) and their downstream
signal mediator signal transducer and activator of transcription 3 (STAT3) which are 
activated by e.g. tumor necrosis factor alpha (TNFα) through TNF receptor 2 (Lecour
2009). Cardioprotection in ischemia-reperfusion by the SAFE pathway is
independent of the RISK pathway (Lecour et al. 2005).
15 
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2.1.3 Current treatment of ischemic heart disease and 
myocardial infarction
As ischemic heart disease is mostly caused by lifestyle factors, treatment of chronic
or stable ischemic heart disease includes lifestyle adjustments, such as cessation of
smoking, appropriate diet and exercise. Additionally, symptoms, the course of the
disease, and prognosis can be adjusted by pharmacological therapies, including beta-
blockers, calcium channel blockers, short- and long-acting nitrates, antiplatelet and
antithrombotic medications (e.g. acetylsalicylic acid and clopidogrel), statins and
other lipid lowering drugs, angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists
(MRA), neprilysin antagonists and diuretics (Knuuti et al. 2020).
Treatment of acute myocardial infarction aims for timely reperfusion of the
heart, either through percutaneous coronary intervention (PCI) or pharmacological
fibrinolysis (Ibanez et al. 2018). Additionally, pharmacological therapies used
during and directly after the ischemia and reperfusion include antiplatelet therapies
(e.g. acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, abciximab, eptifibatide
and tirofiban), anticoagulant therapies, ACE inhibitors or ARBs, nitrates and beta-
blockers (Ibanez et al. 2018). Pharmacological therapies are thus mainly the same
ones as used for the treatment of the stable disease. The target of the therapy is the
reperfusion, inhibiting coronary restenosis by platelet inhibition and reducing the
workload of the heart. No therapies which are directly cardioprotective or, even
better, regenerative at the level of cardiomyocytes are currently in use. Noteworthy
however, antiplatelet therapeutics clopidogrel and cangrelor have shown direct
cardioprotective efficacy in a rabbit infarction model (Yang et al. 2013).
2.1.4 Treatments under development for ischemia-
reperfusion injury
Multiple promising strategies for preventing ischemia-reperfusion injury have been
assessed preclinically and clinically. These therapies target cardiomyocytes or other
involved cell types such as endothelial and other vascular cells, platelets, fibroblasts
or inflammatory cells. In addition to cardioprotection by inhibiting cell death during
ischemia-reperfusion injury, regeneration of cardiomyocytes e.g. through forcing the
cells to re-enter cell cycle and divide is another highly studied area (Cahill et al.
2017). Here, the focus is on the strategies aimed at the salvage of cardiomyocytes
per se and which have proceeded to clinical trials.
A mechanical way to prevent ischemia-reperfusion injury is called ischemic
conditioning in which short periods of induced ischemia and reperfusion are applied. 
This can be done with an angioplasty balloon within the coronary artery before
ischemia (in elective settings) or directly after the reperfusion (Davidson et al. 2019). 
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The procedure is called ischemic pre- or post-conditioning, respectively (Davidson 
et al. 2019; Heusch 2015). Another way is to cause ischemia-reperfusion remotely
to another organ before, during or after the reperfusion, e.g. with a blood pressure 
cuff on a limb (Hausenloy et al. 2019). This is called remote ischemic conditioning.
The phenomenon of ischemic preconditioning was first described by Murry et al.
who demonstrated reduction of infarct size in dogs by four cycles of five-minute
occlusion of circumflex coronary artery prior to a 40-minute occlusion (Murry et al. 
1986). Cardioprotective mechanisms of ischemic conditioning are not totally clear
but they can be mediated by humoral or neuronal mechanisms or locally (Heusch
2015). Intracellular signaling mechanisms activated by ischemic conditioning
include, among many others, the RISK pathway (Hausenloy et al. 2005; Tong et al.
2000), the SAFE pathway (Lecour et al. 2005), and nitric oxide (NO)-cyclic 
guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway (Penna et al.
2007), as shown in isolated perfused rat hearts. Ischemic conditioning has proceeded
to phase III clinical trials. After successful phase II trials, a large randomized clinical
trial (DANAMI-3–iPOST) addressing the efficacy of ischemic post-conditioning 
failed to reduce mortality and hospitalization due to heart failure (Engstrøm et al. 
2017). Similarly, in a large clinical trial called CONDI-2/ERIC-PPCI remote
ischemic conditioning did not produce significant differences in cardiac death or
hospitalization for heart failure (Hausenloy et al. 2019).
Among the multitude of pharmacological strategies for reduction of ischemia-
reperfusion injury, a few have proceeded to clinical trials. Insulin has been shown to 
reduce infarct size in a perfused rat heart model (Jonassen et al. 2001). The
IMMEDIATE trial assessed the efficacy of glucose-insulin-potassium infusion given 
to infarction patients early in the ischemia but no significant differences in the
clinical outcomes were observed in the whole cohort (Selker et al. 2014). In the
subset of patients with STEMI, however, a significant decrease in mortality, cardiac
arrest and hospitalization for heart failure after one year of follow-up (Selker et al.
2014). Exenatide, a glucagon-like peptide-1 analog used for treatment of type 2
diabetes, has also been reported to decrease infarct size in clinical trials including
STEMI patients (Lønborg et al. 2012; Woo et al. 2013), while no differences in
cardiac death, infarction, stent thrombosis or stroke were observed at 30-day follow-
up (Lønborg et al. 2012). Atrial natriuretic peptide (ANP) has also been shown to
reduce infarct size and improve left ventricular ejection fraction at 6–12 months
when given to patients with acute myocardial infarction (Kitakaze et al. 2007).
Nitric oxide has been studied in two trials with intravenous or intracoronary
administration. In a trial with intracoronary administration of sodium nitrite,
reduction in infarct size was not observed while significant reduction in major
adverse cardiac events at one year in the nitrite group was reported, though with few
cases only (Jones et al. 2015). In a trial with intravenous administration of sodium
17 
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nitrite no significant differences in infarct size were detected (Siddiqi et al. 2014). In
the NOMI trial where inhaled NO was used, reduction of infarcted area was 
demonstrated in inhaled NO-treated patients who had not had intra-arterial or 
intracoronary nitroglycerine (i.e. nitroglycerine-naïve patients) but no significant
differences in clinical outcomes (death, recurrent ischemia, stroke, or
rehospitalizations) were observed (Janssens et al. 2018). 
Cyclosporin A, an inhibitor of MPTP opening (Griffiths & Halestrap 1995), has 
also been considered a promising candidate for ischemic cardioprotection. However,
in two large clinical trials, no significant differences in infarct size or in clinical
outcome were observed (Cung et al. 2015; Ottani et al. 2016). Moreover, several
clinical trials with intracoronary or intravenous adenosine have been performed, and 
a meta-analysis indicated that intracoronary adenosine protected from heart failure
while the individual trials did not demonstrate significant efficacy (Bulluck et al.
2016). Larger trials with intracoronary adenosine are thus warranted. Finally,
metoprolol, a beta-blocker, has been considered to have direct cardioprotective
efficacy (Hausenloy et al. 2017a). In the METOCARD-CNIC trial, intravenous
metoprolol prior to PCI reduced both infarct size and hospitalization for heart failure
(Ibanez et al. 2013; Pizarro et al. 2014). On the other hand, in the EARLY BAMI
trial no differences in infarct size were detected although there was a reduction in
malignant arrhythmias (Roolvink et al. 2016). These clinical trials and their
outcomes are summarized in Table 1.
Suggested reasons for the failure of translation of ischemia-reperfusion therapies 
to clinic include differences between preclinical models and human, duration and
setting of ischemia, comorbidities and concurrent medical therapies, and the 
capability of the therapeutics to reach the ischemic myocardium, affected by the lack
of circulation in the heart during ischemia (Davidson et al. 2019). One noteworthy
reason is also age. Animal models used in the preclinical trials are mostly healthy
and young, and the ischemia is artificially produced by coronary artery ligation
(Hausenloy et al. 2017a). Mostly preclinical models lack the effects of slow
deterioration of the heart and vessels and prolonged ischemic stress typical for
ischemic heart disease in human. There are, however, animal models which mimic
the effects of e.g. hypertension, hyperlipidemia and atherosclerosis on the heart
(Ferdinandy et al. 2014). Additionally, comedication often seen in patients with
ischemic heart disease may affect cardioprotection and these effects of certain drugs, 
such as antidiabetics and statins, have been studied in animal models (Ferdinandy et
al. 2014). In designing the future clinical trials, patient selection, drug dosing and
timing should be carefully considered (Hausenloy et al. 2017a). As many of the
cardioprotective strategies act via inhibiting redundant mechanisms of cell death,
approaches with single modalities may not be sufficient, and synergistic strategies
targeting multiple pathways may be necessary (Davidson et al. 2019; Hausenloy et
18
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al. 2017a). Another important aspect in cardioprotection is the timing of the
intervention, i.e. before or after the reperfusion (Davidson et al. 2019). A novel way
to offer cardioprotection would be to administer a pharmacological agent before the
ischemia, i.e. as prophylaxis before the onset of an acute ischemic event. This could
be used as secondary prevention in patients with known ischemic heart disease and
possibly a prior infarction.
Table 1. Summary of clinical trials of ischemia-reperfusion therapies. Result abbreviations: 0,
neutral outcome; +, significant result for a subset of patients or for a surrogate marker
(e.g. reduction in infarct size); ++, significant result for a clinical outcome (e.g. cardiac
death or hospitalization for heart failure). Phase information was retrieved from
ClinicalTrials.gov or from the study article, when available. N/A, not available.
References for each study are stated in the preceding paragraph.
THERAPEUTIC APPROACH TRIAL NAME(S) TRIAL PHASE RESULT
Ischemic post-conditioning DANAMI-3-iPOST III 0
Remote ischemic conditioning CONDI-2/ERIC-PPCI N/A 0
Glucose-insulin-potassium IMMEDIATE III +
Exenatide N/A, EMPIRE I, IV +
ANP J-WIND-ANP, J-WIND-KATP N/A +
Intracoronary sodium nitrite NITRITE-AMI II ++
Intravenous sodium nitrite NIAMI II 0
Inhaled nitric oxide NOMI II +
Cyclosporin A CYCLE, CIRCUS II, III 0
Adenosine meta-analysis N/A ++
Metoprolol METOCARD-CNIC, EARLY BAMI IV, N/A ++, 0
2.2 Heart failure
2.2.1 Pathophysiology of heart failure
Heart failure is a clinical syndrome defined by characteristic signs and symptoms,
such as fatigue, shortness of breath, peripheral edema and pulmonary crackles, which
result in reduced cardiac output and/or elevated intracardial pressures (Ponikowski
et al. 2016). One important diagnostic factor is ejection fraction (EF) which means
the amount of blood pumped from the left ventricle, measured in percentage. In heart
failure with reduced ejection fraction (HFrEF), EF is < 40% and in heart failure with 
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preserved ejection fraction (HFpEF), EF is ≥ 50% (Ponikowski et al. 2016; Yoon &
Eom 2019). In HFpEF, EF is thus of normal range (defined as ≥ 50%), but the 
patients exhibit typical heart failure symptoms. Left ventricular wall thickness is
often increased and there are potentially problems with diastolic filling of the
ventricle, but the term diastolic dysfunction should not be used interchangeably with
HFpEF (Ponikowski et al. 2016). Additionally, heart failure patients with EF
between 40 and 49% are currently defined as having heart failure with mid-range EF
(HFmrEF) (Ponikowski et al. 2016). Classification of heart failure types according
to EF is important therapy-wise: traditional pharmacological treatments are effective
for HFrEF while for HFpEF there are currently no well-defined treatment strategies 
(Yoon & Eom 2019).
There are multiple causes underlying heart failure and the problem can affect the
myocardium itself, endo- or pericardium, cardiac valves, rhythm and conduction
(Ponikowski et al. 2016). The major risk factors for heart failure are ischemic heart
disease, hypertension, diabetes and obesity (Dunlay et al. 2009). In addition to
acquired causes, there is fairly strong inherited predisposition to heart failure (Lee et
al. 2006; Lindgren et al. 2018) as discussed below.
2.2.2 Genetics of heart failure
Estimates of heritability of sporadic heart failure range from 18 to 26% (Lee et al.
2006; Lindgren et al. 2018). A distinct entity among heart failure subtypes are the
familial cardiomyopathies which eventually cause heart failure, such as dilated
cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), arrhythmogenic 
cardiomyopathy (AC) and restrictive cardiomyopathy (RCM) (Cahill et al. 2013).
These syndromes are often caused by a monogenic, dominant mutation and are often
early onset. HCM is the most common inherited heart disease and currently
approximately 60% of the cases are explained by characterized mutations in
sarcomeric genes, most frequently in MYH7 (myosin heavy chain 7, cardiac muscle,
beta) and MYBPC3 (myosin-binding protein C, cardiac) (Cahill et al. 2013). DCM
can be caused by acquired causes such as ischemia, infection and toxins, as well as 
due to a genetic cause. The genetic background of DCM is diverse, and in the familial
forms of DCM causative mutations are identified in 30-35% of the cases (Cahill et 
al. 2013), while estimates of up to 65% of inherited background of DCM have been
published (Petretta et al. 2011). The most frequently mutated genes in DCM include
TTN (titin), LMNA (lamin A/C), MYH7 and TNNT2 (cardiac troponin T) (Cahill et 
al. 2013).
Sporadic heart failure is a polygenic disorder, and there are numerous potential
minor genetic variants contributing to its pathogenesis (Guo et al. 2016; Li & Zhang
2017). Among noteworthy examples are the members of the renin-angiotensin-
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aldosterone pathway, such as ACE, AT1R (angiotensin II type 1 receptor), and AGT
(angiotensinogen) (Guo et al. 2016). Association of an insertion-deletion (I/D)
polymorphism in ACE to heart failure incidence has been studied widely with
contradictory results, and a meta-analysis found no significant association (Bai et al.
2012). ACE D allele has been, however, shown to be associated with improved
outcome when patients are treated with high-dose ACE inhibitor and beta-blockers,
although with low-dose ACE inhibitor treatment there were more adverse events in
carriers of the D allele (McNamara et al. 2004). A recent meta-analysis has also
found an association between the D allele and development of left ventricular
hypertrophy (Fajar et al. 2019). 
Another set of genes closely related to the disease pathogenesis are the genes
encoding adrenergic receptors such as ADRB1 (adrenoceptor beta 1), ADRB2
(adrenoceptor beta 2), and ADRA2C (adrenoceptor alpha 2C) (Guo et al. 2016). 
These genes have several variants which have been studied according to heart failure
prognosis, susceptibility, and treatment outcomes. ADRB1 Arg389Gly variant has
been shown to be associated with reduced treatment efficacy of beta-blockers (Liu
et al. 2012; Parikh et al. 2018). Reports about the ADRB2 Arg16Gly variant have
shown inconsistent associations with heart failure (Guo et al. 2016), while a recent
study demonstrated worse prognosis and better response to beta-blockers in Gly16
allele carriers (Huang et al. 2018). An interesting modulator of therapeutic response
to the beta-blocker metoprolol is the hepatic enzyme CYP2D6 accounting for
metabolism of metoprolol. Genetic variants cause decreased or increased enzymatic
activity of CYP2D6. In patients with decreased enzymatic activity of CYP2D6, i.e.
poor and intermediate metabolizers, plasma concentrations and efficacy of
metoprolol are increased (Rau et al. 2009). A pharmacogenetic dosing guideline
suggests dose reductions in poor and intermediate CYP2D6 metabolizers and, on the
other hand, dose increase in ultrarapid CYP2D6 metabolizers (Swen et al. 2011).
Only a few large-scale all-cause heart failure GWAS have been published and
they have identified a handful of variants significantly associated with heart failure
(Li & Zhang 2017). Smith et al. identified two heart failure incidence-associated loci
with a P-value < 5 x 10-7 (Smith et al. 2010). The closest genes to these identified
loci are USP3 (ubiquitin specific peptidase 3) and LRIG3 (leucine rich repeats and
immunoglobulin like domains 3) (Smith et al. 2010). Another study from the same
cohorts identified one intronic variant in CMTM7 (CKLF-like MARVEL 
transmembrane domain containing 7) to be associated with heart failure mortality
(Morrison et al. 2010). Cappola et al. identified two heart failure-associated intronic
variants with a P-value < 6 x 10-5 (Cappola et al. 2010), the other one of which at
HSPB7 was later shown to be linked to a likely functional variant in CLCNKA (ClC-
Ka, (renal) chloride voltage-gated channel Ka) (Cappola et al. 2011).
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A more recent GWAS identified several novel loci associated with heart failure,
from which a few mediated their effect through risk factor associations, such as
ischemic heart disease, atrial fibrillation, or obesity (Shah et al. 2020). Altogether, 
the number of identified individual variants is low compared to other cardiovascular
disorders, and most of the heritability of heart failure may be more attributable to
subphenotypes of the disease than to a common final pathway (Shah et al. 2020). As
biobanks currently allow for even larger GWAS cohorts, and also a possibility to
define detailed subclasses of disease phenotypes, the heart failure GWAS are finally
gaining the needed power and accuracy in the mixed landscape of multiple etiologies
of the disease. Aragam et al. performed GWAS both on all-cause heart failure and
on a defined subclass of cases: individuals with left ventricular dysfunction without
ischemic heart disease (non-ischemic cardiomyopathy, NICM) (Aragam et al. 2019). 
They identified a strong association with NICM for a variant at BAG3 (BCL2-
associated athanogene 3), earlier associated with DCM (Esslinger et al. 2017). The
same variant was later found to be associated with sporadic heart failure (Shah et al.
2020). Additionally, association with NICM was also detected for a variant at
CLCNKA (Aragam et al. 2019).
A few loci have thus been eventually confirmed by multiple GWAS analyses and
the landscape of central genes and signaling pathways is starting to shape up. Many 
of these loci still need characterization of the functional mechanisms underlying the
pathogenesis as well as of prognostic and therapeutic significance.
2.2.3 Current treatment of heart failure
Current pharmacological therapies for chronic HFrEF include ACE inhibitors or 
ARBs, beta-blockers, MRAs, neprilysin inhibitors, ivabradine, diuretics, and digoxin 
(Ponikowski et al. 2016). Treatments aim at reducing the congestion and workload
of the heart, thus relieving symptoms. Additionally, some treatments, such as ACE
inhibitors, beta-blockers, MRAs and a neprilysin inhibitor combined with an ARB
(sacubitril and valsartan) reduce mortality and morbidity (Ponikowski et al. 2016). 
For HFmrEF and HFpEF, there are currently no treatment strategies with sufficient
evidence for improved survival and merely diuretics and treatment of comorbidities
are recommended (Ponikowski et al. 2016). Additionally, none of the treatments so 
far have been aimed at regeneration of the heart.
2.2.4 Treatments under development for heart failure
Clinical trials assessing SGLT2 (sodium-glucose cotransporter 2) inhibitors, 
originally used for type 2 diabetes treatment, in the treatment of heart failure have
been performed. In the DAPA-HF trial on HFrEF patients, dapagliflozin reduced
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heart failure worsening and cardiovascular deaths in diabetic as well as non-diabetic
patients (McMurray et al. 2019). Interestingly, another SGLT2 inhibitor
empagliflozin has been shown to reduce left ventricular wall mass and improve
diastolic function in a rat model of HFpEF (Connelly et al. 2019), and clinical trials
are underway to specifically address the efficacy of SGLT2 inhibitors in HFpEF
patients. Another therapeutic approach for HFpEF which has proceeded to clinical
trials is the combination of neprilysin inhibitor sacubitril with valsartan (an ARB).
The latest phase III trial with this combination against valsartan alone in HFpEF
patients was neutral in cardiovascular deaths and heart failure hospitalizations 
overall, although in female patients the reduction was significant with the
combination of sacubitril and valsartan (Solomon et al. 2019). NO-cGMP-PKG
signaling is considered a promising therapeutic target for HFpEF, which is also the
pathway the neprilysin inhibitors act upon, and novel therapies with e.g. nitrites and
phosphodiesterase-5a inhibitors targeting the pathway are being assessed (Yoon &
Eom 2019; Zakeri & Cowie 2018).
Regeneration of cardiomyocytes to prevent or treat heart failure is an intriguing
option, although difficult as cardiomyocytes mostly stop dividing and exit cell cycle
after birth. Several approaches to regenerate heart muscle have been proposed and
tested in preclinical models, e.g. with transplantation of induced pluripotent stem cell
(iPSC)-derived cardiomyocytes or embryonic stem cells and activation of
cardiomyocyte proliferation with exogenous ligands such as neuregulin-1 (NRG-1), 
fibroblast growth factor 1 (FGF-1), or insulin-like growth factor 1 (IGF-1) (Cahill et 
al. 2017). NRG-1 has been tested in clinical trials on stable heart failure patients and
a relatively recent phase I trial using cimaglermin, full-length recombinant NRG-
1˜3, improved ejection fraction over three-month follow-up (Lenihan et al. 2016).
2.3 Receptor tyrosine kinases
2.3.1 Structure and activation of receptor tyrosine kinases
Protein tyrosine kinases are enzymes which phosphorylate other proteins on tyrosine
residues as a means of signal transduction and regulation within and between cells.
Among over 90 tyrosine kinases, 55 receptor tyrosine kinases (RTK) form a
subfamily of cell surface-located, transmembrane proteins which bind extracellular
ligands and mediate their signal inside of the cell (Blume-Jensen & Hunter 2001;
Wheeler & Yarden 2015). RTKs regulate central cellular processes such as
proliferation, migration, survival and metabolism, and are involved in disease
pathogenesis, especially in cancer (Lemmon & Schlessinger 2010) as well as in
cardiac diseases and development of the heart (Cahill et al. 2017).
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The structure of RTKs is roughly similar among family members: extracellular
domain contains the ligand binding site; transmembrane domain consists of a single
hydrophobic α helix; and intracellular domain (ICD) contains the tyrosine kinase
domain with its regulatory element, the activation loop (Lemmon & Schlessinger
2010). When not phosphorylated, the activation loop inhibits the kinase domain
(Hubbard & Till 2000). A common event in the initiation of RTK signal transduction 
upon ligand binding is receptor dimerization followed by phosphorylation of the
activation loop in trans by the dimer partner or in cis by autophosphorylation
(Hubbard & Till 2000). This leads to subsequent phosphorylation of tyrosine
residues in the c-terminal tail of the RTK and activation of intracellular signaling
pathways.
2.3.2 Signaling pathways activated by RTKs
Activation of intracellular signaling pathways involves the binding of signaling and 
adaptor proteins to the phosphorylated docking sites at the intracellular domain of
an RTK via the Src-homology 2 (SH2) or phosphotyrosine-binding (PTB) domains
of the downstream signaling proteins (Blume-Jensen & Hunter 2001). Among the
many pathways activated by RTKs, central examples include the mitogen-activated
protein kinase (MAPK) pathway, the PI3K-Akt pathway, the phospholipase C
gamma (PLC-γ) pathway, and the JAK-STAT pathway. The pathways are illustrated 
in Figure 1.
RTKs activate the MAPK pathway by recruiting the growth factor receptor-
bound protein 2 (GRB2) – son of sevenless (SOS) complex, which in turn activates 
RAS (Lemmon & Schlessinger 2010). Subequently, RAS activates the Raf-MEK-
ERK pathway. Phosphorylated ERK translocates to the nucleus and regulates
through transcription e.g. cell cycle progression, cell death or proliferation (Rose et
al. 2010). In the heart, ERK activity can promote hypertrophy or cardioprotection
during ischemia (Rose et al. 2010). Another important kinase among the MAPKs is
the stress-activated p38 which is activated by a large variety of extracellular stress
stimuli leading to activation of downstream kinases such as MEKK1-4 or TAK1 and
subsequently MKK3, -6 and -4 (Rose et al. 2010). Different subunits of p38 are
activated and necessary in ischemic conditioning (Heusch 2015) but, on the other
hand, the inhibition of p38, most likely the α subunit, has been shown to be
cardioprotective in preclinical models (Rose et al. 2010). Additionally, p38α 
inhibition has been shown to enable proliferation of adult rat cardiomyocytes (Engel
et al. 2005).
RTKs activate the PI3K pathway by binding of PI3K through its SH2 domains
which leads to conversion of phosphatidylinositol (4,5)-bisphosphate (or
phosphoinositol-2-phosphate, PIP2) into phosphatidylinositol (3,4,5)-trisphosphate
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(phosphoinositol-3-phosphate, PIP3) (Blume-Jensen & Hunter 2001). Additionally,
Ras kinase can activate PI3K via directly binding to it (Blume-Jensen & Hunter
2001). PIP3 recruits Akt and its activator kinase PDK1 to the cell membrane which
leads to Akt phosphorylation and activation (Blume-Jensen & Hunter 2001). Akt
itself has multiple targets within the cell and its activity leads to e.g. proliferation
and inhibition of apoptosis (Manning & Cantley 2007). Together, the activated 
PI3K-Akt and MAPK/ERK pathways in the heart are called the RISK pathway
which is crucial for cardioprotection in ischemia-reperfusion injury.
Another RTK-activated pathway using phosphoinositol as a signal mediator is
the PLC-γ pathway. RTKs phosphorylate PLC-γ, after which the activated PLC-γ
hydrolyzes PIP2 to inositol (1,4,5)-trisphosphate (inositol trisphosphate, IP3) and
diacylglycerol (DAG) (Lemmon & Schlessinger 2010; Rhee 2001). DAG activates 
PKC and IP3, in turn, increases intracellular calcium levels (Rhee 2001). Subsequent
signaling activities regulate e.g. cellular migration and survival (Suh et al. 2008). 
Activity of PKC is involved in ischemic preconditioning through e.g. translocation
to sarcoplasmic reticulum and subsequent reduction of calcium content (Heusch
2015).
RTKs can activate STAT signaling directly or through phosphorylation of JAKs
(Blume-Jensen & Hunter 2001). STATs are encoded by seven genes in human (Yu 
et al. 2009). They are activated through phosphorylation which leads to their
dimerization and nuclear translocation, and in the nucleus they act as transcription
factors, regulating the expression of genes related to e.g. survival and proliferation
(Yu et al. 2009). Especially STAT3 has been shown to have cardioprotective effects
in multiple pathological conditions, such as ischemia-reperfusion, hypertrophy and
heart failure in murine models in vivo (Harhous et al. 2019). STAT3 is central
member of the cardioprotective SAFE pathway.
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Figure 1. Schematic presentation of common signaling pathways activated by RTKs upon ligand
binding and receptor dimerization. Abbreviations: ECD, extracellular domain; TMD,
transmembrane domain; ICD, intracellular domain; P, phosphorylated tyrosine residue.
2.3.3 Regulated intramembrane proteolysis
In addition to the classical signal trandsuction by ligand binding, dimerization,
autophosphorylation and activation of downstream signaling proteins, a subset of
RTKs can undergo a process called regulated intramembrane proteolysis (RIP)
(Merilahti et al. 2017). RIP is initiated, often after ligand binding, by cleavage of the
extracellular domain of an RTK by a protease (also known as sheddase) belonging 
e.g. to the families of disintegrin and metalloproteases (ADAM) or matrix
metalloproteases (MMP) (Beel & Sanders 2008). This exposes a cleavage site in the 
transmembrane domain which is cleaved by another protease presented in the form
of γ-secretase complex (Beel & Sanders 2008) (Figure 2). Released ICD can
translocate to the nucleus and act there as a transcriptional regulator (Merilahti & 
Elenius 2019). Altogether 27 RTKs have been shown to undergo RIP (Merilahti et 
al. 2017). Additionally, an RTK can translocate into the nucleus as an intact
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molecule, as has been shown e.g. for epidermal growth factor receptor (EGFR,
ErbB1) (Marti et al. 1991).
Figure 2. Schematic illustration of regulated intramembrane proteolysis (RIP) of an RTK. RIP starts
with the cleavage of the ECD by a sheddase which is followed by γ-secretase-mediated 
release of the ICD. Abbreviations: ECD, extracellular domain; TMD, transmembrane
domain; ICD, intracellular domain.
2.3.4 ErbB receptor family
ErbB receptor family (named originally as v-erb-a erythroblastic leukemia viral
oncogene homolog, also known as EGFR or HER family) consists of four members
in mammals, EGFR or ErbB1 (Ullrich et al. 1984), ErbB2 (HER2) (Stern et al. 1986), 
ErbB3 (HER3) (Plowman et al. 1990) and ErbB4 (HER4) (Plowman et al. 1993). 
They have at least 11 ligands (Stein & Staros 2006). The binding specificities of the
ligands are presented in Table 2 (Linggi & Carpenter 2006). Notably, ErbB2 has no
high-affinity ligand detected so far.
ErbB receptors are strongly expressed in the heart, skeletal muscle, central
nervous system, mammary gland, kidney, lung, and their knockout produces
problems in development of these organs (Chan et al. 2002; Chen et al. 2000; Elenius
et al. 1997; Erickson et al. 1997; Gassmann et al. 1995; Lee et al. 1995; Sibilia et al.
2007). The role of ErbBs in cardiac development, as well as in cardiovascular
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diseases, is discussed in detail below. ErbB receptors have also multiple implications
in cancer pathogenesis, especially breast, lung, brain, skin, ovarian and head and 
neck cancers (Sibilia et al. 2007).
ErbB receptors are mainly activated in the manner common for RTKs, including
ligand binding, homo- or heterodimerization and phosphorylation of the kinase
domain (Linggi & Carpenter 2006). However, ErbB receptor activation does not
require phosphorylation of the autoinhibitory activation loop but instead an allosteric
mechanism allows activation of the kinase domains in the dimer which results in
phosphorylation and activation (Lemmon & Schlessinger 2010). Several
mechanisms to inhibit or modify ErbB-mediated signals have been identified, 
notably dephosphorylation by phosphatases (Lemmon & Schlessinger 2010), 
ubiquitination (see chapter 2.3.1 for detailed definition) and subsequent
internalization and degradation of the receptor (Carraway 2010), or SUMOylation
followed by nuclear localization and either repression (Sundvall et al. 2012) or
enhancement (Knittle et al. 2017) of signaling activities. 
Among the ErbB family, ErbB4 is an exception in its ability to undergo RIP.
Two alternatively spliced isoforms at the juxtamembrane (JM) region of ErbB4 exist:
JM-a exclusively carrying exon 16 and JM-b exclusively exon 15 (Elenius et al.
1997). JM-a is the only cleavable isoform (Elenius et al. 1997). Extracellular domain
of JM-a is cleaved by the sheddase TNFα converting enzyme (TACE) / ADAM17
which generates an 80-kilodalton (kDa) membrane-bound fragment. This is
subsequently cleaved by γ-secretase, leading to the release of an ICD which can
translocate into the nucleus (Ni et al. 2001), and regulate transcription and 
differentiation (Knittle et al. 2017; Merilahti et al. 2017; Muraoka-Cook et al. 2006;
Paatero et al. 2012). In addition to JM isoforms of ErbB4, its cytoplasmic part varies
by inclusion (CYT-1 isoform) or exclusion (CYT-2 isoform) of exon 26. CYT-1 can
directly bind and activate PI3K (Elenius et al. 1999). Additionally, it can bind the
ubiquitin ligase Itch which leads to ubiquitination and endocytosis of CYT-1 
(Sundvall et al. 2008).
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Table 2. Ligands of ErbB family receptors (modified from Linggi and Carpenter 2006).
Abbreviations: EGF, epidermal growth factor; HB-EGF, heparin-binding EGF-like growth 
factor; TGF-α, transforming growth factor alpha.
LIGAND EGFR ErbB2 ErbB3 ErbB4
Amphiregulin x
EGF x
Epigen x
TGF-α x
Betacellulin x x
Epiregulin x x
HB-EGF x x
Neuregulin-1 x x
Neuregulin-2 x x
Neuregulin-3 x
Neuregulin-4 x
2.3.5 ROR receptors
ROR (receptor tyrosine kinase-like orphan receptor) family of RTKs consists of two 
members, ROR1 and ROR2 (Masiakowski & Carroll 1992). The name of the family
stems from the notion that there would be no specific ligands for the receptors but it
was later discovered that WNT5A can bind and activate both RORs (Fukuda et al.
2008; Liu et al. 2008; Oishi et al. 2003; Yu et al. 2016). RORs heterodimerize with
each other (Yu et al. 2016). Additionally, homodimerization of ROR2 (Liu et al.
2008) and ROR1 (Hojjat-Farsangi et al. 2013) has been demonstrated. Activation of
RORs causes phosphorylation, binding of signaling proteins to the phosphorylated 
docking sites, and activation of pathways common for RTKs, such as the PI3K, JAK-
STAT, and MAPK pathway (Hojjat-farsangi et al. 2014). Additionally, ROR
receptors can act as coreceptors for the GPCR Frizzled (Park et al. 2015) and
dimerize with other RTKs, such as EGFR (Yamaguchi et al. 2012). WNT5A-
mediated activation of ROR1/ROR2-Frizzled complex leads to activation of
relatively less studied RTK signaling pathways, such as planar cell polarization
pathway through Rho-Rac-Cdc42 proteins, as well as to inhibition of the canonical
WNT pathway (Kamizaki et al. 2020).
RORs are expressed in many tissues during embryonic development, especially
in neural tissues, heart, muscle, bones, limb, and gut (Al-Shawi et al. 2001; Matsuda
et al. 2001; Oishi et al. 1999). Knockout of Ror2 in mice causes dwarfism, cyanosis,
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dysplastic lungs, short limbs and tails, and ventricular septal defects (VSD) (Oishi et 
al. 2003; Takeuchi et al. 2000). A similar phenotype have been reported for Wnt5a
deficient mice (Oishi et al. 2003). Ror1 knockout alone in mice does not cause
cardiac or skeletal abnormalities but the mice die postnatally due to respiratory
problems and unexpanded alveoli in the lungs (Nomi et al. 2001). Defects in cardiac 
development due to knockout of ROR receptors are discussed later in detail.
Expression of RORs is decreased in normal adult tissues compared to the levels 
in embryo. In mouse, Ror2 expression is virtually absent in adult tissues (Oishi et al.
1999). Similarly, Ror1 expression is decreased by age and in the adult mouse, 
expression is mainly detected in the heart (Oishi et al. 1999). Strong expression of
ROR1 in adult human tissues has been shown in pancreatic, parathyroid and
gastrointestinal tissues (Balakrishnan et al. 2017). ROR1 expression in adult heart
was not detected by Balakrishnan et al. (Balakrishnan et al. 2017) Dave et al.
identified a truncated 50-kDa isoform and only very low expression of the full length
receptor in pediatric heart samples, and additionally cytoplasmic expression in adult 
heart (Dave et al. 2012). However, Sharma et al. detected ROR1 and ROR2 mRNA 
expression in human iPSC-derived cardiomyocytes (Sharma et al. 2017). Although 
ROR expression is significantly reduced in adult tissues, RORs seem to have central
roles e.g. in tissue repair after brain, intestinal and skeletal injuries (Kamizaki et al.
2020). 
RORs are implicated in pathogenesis of several cancers, such as leukemias,
melanoma and prostate, breast, ovarian and colon cancer (Hojjat-farsangi et al.
2014). ROR1 is being assessed as a target for cancer therapy. Cirmtuzumab, a
ROR1-targeting monoclonal antibody, has been developed primarily for the
treatment of chronic lymphocytic leukemia and has been tested in phase I trials (Choi
et al. 2015). Furthermore ROR2-WNT5A signaling is centrally involved in
pathogenesis of bone diseases, such as for osteoporosis (Kamizaki et al. 2020). 
Finally, given the central role of RORs in skeletal and limb development, mutations
in ROR2 cause recessive Robinow syndrome with abnormal facial features, short
limbs, genital and skeletal anomalies (Bokhoven et al. 2000), and Brachydactyly
type B with distally shortened fingers and toes (Oldridge et al. 2000).
2.3.6 RTKs in cardiac development
Several RTKs are centrally involved in the embryonic development of the heart, as
is the case e.g. with the whole ErbB family. Loss of Erbb2 is lethal at embryonic day 
E10.5 in mice due to defects in cardiac trabeculation (Chan et al. 2002; Lee et al.
1995). Knockout of Erbb4 in mice leads to a similar phenotype (Gassmann et al.
1995) and concordantly, a similar phenotype was detected in Nrg1-deficient mice
which also died at E10.5 (Meyer & Birchmeier 1995). Loss of Egfr in mice results 
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in defects of semilunar (i.e. aortic and pulmonary artery) valve development which
causes thickened valves leaflets, aortic stenosis and regurgitation and subsequent
cardiac hypertrophy (Chen et al. 2000). Erbb3-knockout mice die at E13.5 due to
poorly developed cardiac valves and blood regurgitation (Erickson et al. 1997).
Both members of the ROR family are also involved in heart development. Ror2-
deficient mice die postnatally, are cyanotic and have a ventricular septal defect
(VSD) (Takeuchi et al. 2000). Loss of Ror1 alone in mice produces no heart defects 
but the mice die after birth due to respiratory problems (Nomi et al. 2001). Loss of
both Ror1 and Ror2 in mice leads, however, to more severe heart phenotype than
Ror2-knockout alone, as VSD is accompanied with transposition of the great arteries
(Nomi et al. 2001).
Other examples of RTKs involved in the heart development include members of
anaplastic lymphoma kinase / leukocyte tyrosine kinase (ALK/LTK), Eph, platelet-
derived growth factor receptor (PDGFR), angiopoietin (TIE) and vascular
endothelial growth factor receptor (VEGFR) families. Transgenic overexpression of
LTK in mice results in cardiac hypertrophy, reduced cardiac output and degeneration
of cardiomyocytes (Honda et al. 1999). Loss of Epha3, a member of the Eph receptor
family, in mice generates hypoplastic valves and atrial septal defect and leads to
lethality of approximately 75% of the mice shortly after birth (Stephen et al. 2007). 
On the other hand, loss of Ephrin-A1, a ligand of EphA3 among other receptors,
leads to thickened aortic and mitral valves in mice which are viable but have
problems in cardiac function (Frieden et al. 2010). As a sign of necessity of PDGFR-
related signaling, Pdgfb-knockout mice die perinatally with problems in kidney
development, dilated heart and hemorrhages (Levéen et al. 1994). Mice lacking
PDGFR˜ (Mellgren et al. 2008; Van Den Akker et al. 2008) or PDGFB (Van Den
Akker et al. 2008) have been shown to develop thinned, hypoplastic myocardium
and VSD. The phenotype in PDGFR˜-deficient mice is accompanied with
abnormalities in coronary development (Mellgren et al. 2008). Homozygous deletion 
of Tie2 in mice leads to embryonal lethality at E9.5 and serious defects in
development, which is likely due to loss of interaction between endocardium and
myocardium as TIE2 is expressed in endothelial cells (Dumont et al. 1994). 
Knockout of Vegfb, encoding a ligand for VEGFRs, has been shown to cause reduced
heart size in mice and vascular dysfunction after coronary occlusion (Bellomo et al.
2000).
2.3.7 RTKs with therapeutic potential in myocardial
ischemia-reperfusion
Regulation and therapeutic potential of ErbB family members EGFR, ErbB2 and 
ErbB4 in the ischemic heart have been widely studied. In ischemic human heart
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compared to normoxic control heart, expression of ERBB2 and NRG1 have been 
shown to be decreased at mRNA level, while expression of EGFR and ligands
HBEGF (heparin-binding EGF-like growth factor) and NRG2 is increased (Munk et
al. 2012). In the same study, EGFR phosphorylation was decreased while ErbB2 and
ErbB4 phosphorylation were increased by hypoxia in HL-1 cardiomyocytes, and 
administration of HB-EGF rescued the cells from reduced viability caused by ErbB2
inhibition with trastuzumab in hypoxia (Munk et al. 2012). Moreover, ErbB2 protein
expression is reduced in hypoxia-reoxygenation treated neonatal rat cardiomyocytes
(Viswanath et al. 2011) and in human hearts with ischemic cardiomyopathy (Gordon 
et al. 2009). Cardioprotective effects of exogenously administrated NRG-1 in 
isolated, infarcted rat heart has been demonstrated (Wang et al. 2018). Similar effect
of endothelial cell-derived NRG-1 in isolated, infarcted mouse heart has been shown
(Hedhli et al. 2011). The mechanism seems to be ErbB4-mediated activation of the
RISK pathway and reduction of apoptosis (Wang et al. 2018). Activation of ErbB2 
and ErbB4 also confer cardioprotection by activating regeneration and proliferation 
of cardiomyocytes, as discussed later.
Transactivation of EGFR by various G protein-coupled receptors (GPCR) is
central in many cardioprotective approaches. EGFR transactivation is necessary e.g. 
in ischemic preconditioning and adenosine-mediated cardioprotection as shown in a
perfused mouse heart model (Williams-Pritchard et al. 2011), in bradykinin-
mediated cardioprotection demonstrated in a perfused rat heart model (Methner et
al. 2009), as well as in opioid receptor-mediated cardioprotection in isolated rabbit
heart (Förster et al. 2007). EGF administration has been shown to be cardioprotective
in ischemia in isolated hearts of both mouse (Lorita et al. 2010) and type 1 diabetic
rats (Akhtar et al. 2012). Contradictory to these findings, two-week inhibition of
EGFR with a (non-specific) inhibitor AG1478 before ischemia reduced infarct size
and apoptosis in rats with type 2 diabetes (Mali et al. 2018). Amphiregulin signaling
through EGFR has been shown to contribute to cardiac fibrosis and shRNA-mediated
amphiregulin knockdown improved cardiac functionality after infarction in mouse
(Liu et al. 2018). Role of EGFR thus seems to be complex in ischemic
cardioprotection, while a large proportion of the evidence so far has shown EGFR
activity to be beneficial for cardioprotection (Reichelt et al. 2017).
Insulin receptor (INSR) is involved in ischemic cardioprotection, and
administration of insulin at reoxygenation has been shown to protect isolated rat 
cardiomyocytes from apoptosis (Jonassen et al. 2000). Insulin, given at early
reperfusion, was also shown to reduce infarction size in isolated rat hearts through
Akt-p70s6 kinase dependent signaling (Jonassen et al. 2001). Protein levels of
VEGFR1, VEGFR2 and IGF-1R, and their ligands VEGFA and IGF-1, have been
shown to be upregulated in porcine heart after ischemia-reperfusion (Infanger et al.
2007). Administration of quinaprilat, an ACE inhibitor, further increased IGF-
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1/IGF-1R expression which correlated with reduced laminin, collagen type IV and
chondroitin sulfate expression, potentially thus mediating the attenuation of cardiac
remodeling (Infanger et al. 2007).
TIE receptors are expressed in the endothelial cells but they affect myocardial
cells through paracrine signaling and vascularization. In a rat model of myocardial
infarction, TIE2 phosphorylation has been shown to be increased, and protein and 
mRNA expression of its ligand angiopoietin-1 were decreased while those of
angiopoietin-2 were increased (Sandhu et al. 2004). Administration of angiopoietin-
1 has been shown to protect cardiac contractility in a mouse infarction model (Lee 
et al. 2011). As cardiomyocytes themselves do not express TIE receptors, the
cardioprotective signaling in cardiomyocytes was shown to be mediated through ˜1 
integrin (Lee et al. 2011).
Yet another RTK involved in ischemic cardioprotection is EphA2 receptor with
its (non-exclusive) ligand Ephrin-A1. In a non-reperfused mouse infarction model,
infarct size was greater and ischemic cardiomyopathy was more severe four weeks 
after infarction in EphA2-deficient mice than in wildtype controls (O’Neal et al.
2014). On the other hand, intramyocardial injection of chimeric Ephrin-A1-Fc has 
been shown to preserve cardiac function and reduce infarct size both in non-
reperfused mouse heart model (Dries et al. 2011), as well as in a mouse ischemia-
reperfusion injury model (DuSablon et al. 2017).
2.3.8 Regenerative potential of myocardium conferred by 
RTKs
In addition to being activated and possibly cardioprotective by reducing infarct size
and cardiomyocyte death in ischemia-reperfusion injury, some RTKs may confer
further protection through direct myocardial regeneration. Central examples are
ErbB2 and ErbB4. Transient induction of constitutively active ErbB2 has been
shown to induce redifferentiation, proliferation and regeneration of cardiomyocytes
which reduces infarct size and preserves cardiac function in a mouse model (D’Uva
et al. 2015). Similarly, activation of ErbB4 by NRG-1 induces proliferation of
mononucleated cardiomyocytes and this leads to reduced infarct size and improved 
cardiac function in mice (Bersell et al. 2009).
Fibroblast growth factor receptors (FGFR) are another family of RTKs involved
in cardiomyocyte proliferation. Administration of FGF-1, a ligand to all FGFRs, 
together with a p38 inhibitor has been shown to induce cardiomyocyte mitosis, 
decrease infarct scar and improve cardiac function in a permanent coronary artery
ligation model in rats (Engel et al. 2006). In a porcine ischemia-reperfusion model,
catheter-based injection of microparticles loaded with either FGF-1 or NRG-1 
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improved cardiac function and increased myocardial vascularization (Garbayo et al.
2016). 
Finally, conditional activation of PDGFR˜ in cardiomyocytes has been shown
promote heart regeneration and preserve cardiac function after non-reperfused
infarction in mice (Yue et al. 2019). Similar regenerative activity was shown also
with myocardial adenoviral expression of constitutively active PDGFR˜ after 
infarction (Yue et al. 2019). Altogether, utilization of RTKs to promote cardiac
regeneration is promising but RTK-based therapies to regenerate myocardium after
ischemia-reperfusion injury have not been assessed in clinical trials for the time
being.
2.3.9 RTKs implicated in heart failure
A few RTKs have been implicated in heart failure pathogenesis and as potential
targets for cardioprotection. ErbB2 and ErbB4 expression are decreased both on
mRNA and protein level in rats with pressure-overload hypertrophy, as the disease
develops from compensatory hypertrophy to heart failure (Rohrbach et al. 1999). 
Similarly, cardiac ErbB2 and ErbB4 expression are decreased in patients with heart
failure, both on mRNA and protein level (Rohrbach et al. 2005). Additionally
decreased ErbB2 phosphorylation has been observed, while NRG-1 protein 
expression is increased (Rohrbach et al. 2005). Moreover, ventricular assistance
device (VAD) treatment, used to unload a failing heart, was shown to increase ErbB2
and ErbB4 expression (Rohrbach et al. 2005). Similar effect of VAD on ErbB2 and
ErbB4 mRNA expression was shown by Uray et al., especially in ischemic
cardiomyopathy, though they contradictorily reported increased ErbB4 expression
in failing hearts compared to controls (Uray et al. 2002). As discussed earlier,
enhancing ErbB signaling through recombinant NRG-1 has been tested as a heart
failure treatment modality in clinical trials with positive results (Lenihan et al. 2016).
VEGFR-mediated signaling governs angiogenesis and through this it affects
cardiovascular disease progression (Ky et al. 2011). Soluble VEGFR1 (FLT1) in
blood has been shown to be associated with severity of heart failure and short
transplant-free and VAD-free survival in the patients with soluble VEGFR1 levels
in the highest quartile (Ky et al. 2011). Furthermore, higher plasma levels of VEGF
ligand (subtype not specified) have been observed in heart failure patients, together
with higher levels of TIE2 and angiopoietin-2 (Chong et al. 2004). Contradictory to 
this, in mice with transverse aortic constriction (TAC)-induced heart failure,
decreased levels of VEGFB mRNA after four weeks of TAC have been observed in
the heart, while increased levels of VEGFC and VEGFD mRNA, together with
increased level of VEGFR3 mRNA, were observed after two weeks (Huusko et al.
2012). However, adenoviral delivery of VEGFB preserved heart function, promoted
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angiogenesis, and reduced cardiomyocyte apoptosis in the mouse model of TAC-
induced heart failure (Huusko et al. 2012). Similarly, adenoviral delivery of VEGFB
prevented heart failure in tachypaced dogs through inhibition of apoptosis and
oxidative stress in cardiomyocytes (Pepe et al. 2010).
AXL, a member of TAM receptor family, has been shown to be upregulated at
protein level in human myocardium with heart failure compared to control hearts, and,
concordantly, high soluble AXL levels in serum were observed in heart failure patients
(Batlle et al. 2014). Disease progression as estimated by hospitalizations, all-cause 
mortality, and transplantations correlated with high soluble AXL levels at one-year
follow-up (Batlle et al. 2014). However, AXL or any other RTK has not yet progressed
to actual clinical use as a biomarker or therapeutic target for heart failure.
2.3.10 Cardiotoxicity of RTK inhibitors
Multiple RTKs are involved in cancer pathogenesis and they are targeted with small
molecule tyrosine kinase inhibitors (TKI) or antibodies in cancer therapies. Given
the central role of RTKs in heart development and diseases as discussed above, it is 
not surprising that certain RTK-targeting therapies produce cardiotoxicity as adverse 
drug effects. A hallmark example of this is trastuzumab, an ErbB2-targeting antibody 
used to treat breast cancer and other cancers with ErbB2 amplification. Trastuzumab 
produces heart failure, which is at least to some extent reversible (Nemeth et al. 2017;
Slamon et al. 2001). Toxicity is especially observed when trastuzumab is combined
with anthracyclines (Nemeth et al. 2017). Potential mechanisms include impaired
NRG-1/ErbB signaling, increased ROS production and apoptosis (Nemeth et al.
2017). As expectable, pan-ErbB inhibitors which target multiple EGFR family
members are potentially cardiotoxic through ErbB2 inhibition, such as has been
shown for lapatinib (Jerusalem et al. 2019) and afatinib (Schuler et al. 2012).
However, in a review of cardiac safety data from afatinib trials, cardiac failure
adverse events were not increased by afatinib as compared to placebo (Ewer et al.
2015).
EGFR inhibition alone has been considered relatively safe from the cardiac point
of view (Chen et al. 2008). However, a case-control study revealed increased risk for
heart failure in patients treated with cetuximab or panitumumab, both EGFR-
targeting antibodies, while there was no increased risk observed with erlotinib and
gefitinib, small molecule inhibitors of EGFR (Gronich et al. 2017).
VEGFRs are targeted with many multi-target TKIs. Sunitinib, which targets e.g. 
PDGFR family receptors in addition to all VEGFRs, has been shown to predispose
to hypertension, left ventricular dysfunction and reversible heart failure (Chu et al.
2007). Apoptosis and mitochondrial injury were suggested as possible mechanisms
(Chu et al. 2007). Pazopanib is a TKI which inhibits e.g. FGFRs and PDGFRs in
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addition to VEGFRs. Pazopanib use has been shown to cause hypertension,
conduction problems and ventricular dysfunction (Pinkhas et al. 2017). A meta-
analysis of VEGFR TKIs (axitinib, cediranib, pazopanib, ramucirumab, sorafenib, 
sunitinib, vandetanib) found evidence of increased heart failure risk associated with
the use of VEGFR TKIs (Qi et al. 2014).
Preclinical models have been developed to predict cardiotoxicity of TKIs. Cheng
et al. demonstrated that a zebrafish model could discriminate a non-cardiotoxic TKI, 
the EGFR inhibitor gefitinib, from known cardiotoxic TKIs sunitinib and sorafenib
(Cheng et al. 2011). The mechanism of sunitinib-induced cardiotoxicity has been
shown to be partly mediated by inhibition of AMPK, an intracellular kinase activated
by e.g. energy depletion (Kerkelä et al. 2009). Sharma et al. used human iPSC-
derived cardiomyocytes to screen cardiotoxicity of TKIs in a high-throughput setting
with multiple readouts (Sharma et al. 2017). They identified VEGFR2/PDGFR-
inhibiting TKIs as highly cardiotoxic and showed that exogenous insulin or IGF-1 
could attenuate the cardiotoxicity (Sharma et al. 2017). Elmadani et al. screened a 
wide compound family of kinase inhibitors, including several TKIs, on neonatal rat
ventricular cardiomyocytes and IGF-1R, PI3Kα and mTOR were identified as
central kinases regulating cardiomyocyte viability (Elmadani et al. 2019). 
2.4 TRIM proteins
2.4.1 Protein control by ubiquitination
Ubiquitination is a process where a small modifier protein called ubiquitin is
covalently attached to another protein, which is referred to as the substrate. Ubiquitin
is a 76-amino acid protein (approximately 8.6 kDa) which is conjugated via its
carboxy terminus to a lysine on the substrate through a three-step process 
(Hatakeyama 2017). First, ubiquitin is activated in an ATP-dependent manner by a
ubiquitin-activating enzyme called E1 by conjugating the C-terminal glycine of
ubiquitin to the E1 itself. Subsequently, ubiquitin is transferred to a ubiquitin-
conjugating enzyme belonging to the E2 class. Finally, by collaboration of the E2 
and an E3 a ubiquitin ligase, ubiquitin is conjugated to a lysine side chain of the
substrate or another ubiquitin, already attached to a substrate (Hatakeyama 2017). 
E3 ligases are divided into three classes: Homologous to E6AP Carboxy Terminus
(HECT), U-Box, and RING finger-containing E3s (Hatakeyama 2017; Meroni & 
Diez-Roux 2005). E3s identify the substrate and the substantially large number of
E3s is possibly due to the needed specificity for a large and diverse group of
substrates (Meroni & Diez-Roux 2005).
Ubiquitin may be conjugated to the substrate as a single ubiquitin
(monoubiquitination, taking place on one or multiple sites per substrate) or as a
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polyubiquitin chain. There are several lysines on the ubiquitin through which they
can be conjugated to each other forming a polyubiquitin chain. The lysine 48 (K48)-
conjugated ubiquitin chains mainly target the substrate protein to proteasomal
degradation by the 26S proteasome, a large protein complex which degrades proteins
(Hatakeyama 2017). Additionally, proteins with ubiquitin chains conjugated by the
other available lysines (K6, K11, K27, K29, K33, K63) or the amino-terminal 
methionine (M1) are implicated in signal transduction, DNA repair, or membrane
trafficking (Hatakeyama 2017; Venuto & Merla 2019). The events of ubiquitination
are schematically illustrated in Figure 3.
Figure 3. Events of ubiquitination of a protein. Ubiquitin is first activated in an ATP-dependent
manner by ubiquitin-activating enzyme E1. Ubiquitin is then transferred to a ubiquitin-
conjugating enzyme E2, which together with a ubiquitin ligase enzyme, E3, transfers the 
ubiquitin to the target protein. Mono- and polyubiquitination target proteins to different
destinations.
2.4.2 TRIM proteins are ubiquitin E3 ligases with various 
functions
TRIMs are a large family of proteins, and most of them function as E3 ubiquitin 
ligases. There are currently more than 80 known TRIM genes in human (Hatakeyama 
2017). The name of the family stems from their characteristic TRIpartite Motif which
consists of a RING finger domain, one or two B-box zinc finger domains, and a
coiled-coil region (Meroni & Diez-Roux 2005). Another name of the family is
RBCC (RING-B-Box-coiled-coil). The RING finger domain is a zinc atom-binding 
motif which is present in many E3 ubiquitin ligases and it is responsible for binding
both RING-containing proteins as well as versatile ubiquitination substrates (Meroni
& Diez-Roux 2005). The B-box motif binds also zinc and it may be involved in 
creating higher order structures of TRIM proteins (Watanabe & Hatakeyama 2017). 
The Coiled-coil domain is involved in homodimerization of TRIMs (Meroni & Diez-
37 
 
 
  
 
  
  
  
    
   
     
      
  
 
 
     
 
  
      
  
        
     
   
 
      
      
  
 
  
   
   
     
   
 
   
  
 
    
  
  
    
    
  
Juho Heliste
Roux 2005; Watanabe & Hatakeyama 2017). TRIMs are divided into 11 subclasses
according to their C-terminal domains, which are diverse and potentially add to the
specificity of interactions between other proteins (Borlepawar et al. 2019).
As for other E3s, ubiquitination by TRIMs may, in addition to classical targeting
for proteasomal degradation, lead to altered transcriptional regulation, membrane
trafficking or subcellular localization of the substrates (Hatakeyama 2017; Meroni
& Diez-Roux 2005). Various TRIMs are involved in regulation of the cell cycle, and
while some function as oncogenes, others act as tumor suppressors (Venuto & Merla 
2019). Furthermore, TRIMs are key factors in autophagy, which is an intracellular
lysosome-dependent protein degradation pathway. In autophagy, TRIMs interact
with target-recognizing proteins such as p62/SQSTM1 which add substrate
specificity to the process (Hatakeyama 2017).
TRIMs are involved in pathogenesis or control of many diseases, such as Opitz
syndrome (a congenital state causing midline defects including hypospadia, cleft lip
and palate, and laryngotracheal abnormalities) and other developmental disorders,
innate immune response to viral infections by for example HIV and influenza A
virus, and muscle atrophy (Watanabe & Hatakeyama 2017). Moreover, 
dysregulation of TRIM expression or chromosomal aberrations which affect TRIM
genes have been shown to be involved in cancer, e.g. acute promyelocytic leukemia
and parathyroid, liver (Watanabe & Hatakeyama 2017), prostate, and breast cancer
(Hatakeyama 2017). 
The physiology of the heart requires a balance of protein synthesis and
degradation. Complex role of ubiquitination in the heart is underscored by the
contradictory evidence from animal models where both prevention and exacerbation 
of hypertrophy and heart failure have been observed as an effect of proteasome
inhibitors (Barac et al. 2017). Moreover, the ubiquitin-proteasome system is 
involved e.g. in regulation of ˜-adrenergic signaling and pathogenesis of ischemia-
reperfusion injury (Barac et al. 2017). Sixty E3 ligases have been identified to have
functional roles in the heart, out of which eight are TRIMs (Borlepawar et al. 2019). 
These TRIMs take part in essential cardiac functions, such as differentiation,
apoptosis, hypertrophy, atrophy, and ischemia (Borlepawar et al. 2019). Their roles
can be either inhibitive or promoting for pathological cardiac conditions, as has been 
shown e.g. for TRIM24 and TRIM32. TRIM24 binds and prevents the degradation
of dysbindin which is targeted for degradation by TRIM32 (Borlepawar et al. 2017). 
Dysbindin activity leads to hypertrophy, and TRIM24 and TRIM32 have opposing
roles in its regulation (Borlepawar et al. 2017). TRIM32 prevents hypertrophy of
cultured cardiomyocytes but on the other hand, overexpression of TRIM32 increases
apoptosis of cardiomyocytes (Borlepawar et al. 2017). TRIM8 is another example of
a TRIM protein whose function predisposes to hypertrophy, as shown in knockout
mice which were protected from hypertrophy after TAC (Chen et al. 2017). 
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2.4.3 The muscle ring finger family members are central 
TRIMs in the heart
The most studied subgroup of TRIMs in the heart are TRIM54, TRIM55 and
TRIM63, the members of the muscle ring finger (MURF) family. MURF family
consists of three proteins, MURF1 or TRIM63, MURF2 or TRIM55 and MURF3 or
TRIM54. TRIM54 and TRIM63 are specifically expressed in striated muscle while
TRIM55 expression has been additionally observed in liver (Centner et al. 2001). 
TRIM55 is expressed strongly in embryonic mouse heart and its expression begins
at E8.5 and peaks at E18.5 (Perera et al. 2011). TRIM55 expression is later reduced
in adult myocardium (Perera et al. 2011). Contrary to this, expression of TRIM63
increases after birth and TRIM54 is virtually expressed only after birth (Perera et al.
2011). MURFs have been shown to colocalize with and affect the organization of
both M- and Z-bands of the sarcomeres, TRIM63 showing colocalization with both
and TRIM55 with M-bands (Centner et al. 2001; Perera et al. 2011).
Mice lacking either Trim55 or Trim63 alone do not demonstrate developmental
abnormalities while double-knockout (DKO) of the both genes causes massive
cardiac hypertrophy and is lethal to majority of the mice pre- or perinatally (Willis 
et al. 2014). Furthermore, the DKO mice demonstrate mild skeletal muscle
hypertrophy (Witt et al. 2008). Although TRIM55 and TRIM63 seem to have
redundant functions in embryonic development, it has been shown that knockout of
Trim63 in mice causes exaggerated hypertrophic response to TAC while knockout
of Trim55 does not (Willis et al. 2007). Antihypertrophic activity of TRIM63 has
been shown be mediated through inhibition of PKCε translocation to focal adhesions
(Arya et al. 2004). Furthermore, TRIM63 overexpression has been detected in 
multiple situations of skeletal muscle atrophy and its deficiency protects from
skeletal denervation atrophy (Bodine et al. 2001). On the other hand, transgenic
overexpression of TRIM63 in mice causes thinning of ventricular wall, inhibition of
creatine kinase activity and rapid progression of heart failure after TAC (Willis et al.
2009). Knockout of Trim54 in mice causes no apparent phenotype in normal
conditions while increased tendency to cardiac rupture, ventricular dilatation and
reduced contractility are observed after myocardial infarction (Fielitz et al. 2007b). 
DKO of Trim54 and Trim63 in mice causes myocardial hypertrophy, decreased
ventricular function and skeletal myopathy (Fielitz et al. 2007a). Finally, DKO of
Trim54 and Trim55 causes aggregate myopathy, impaired cardiac function and 
disturbed calcium handling in cardiomyocytes (Lodka et al. 2016). Balance of
MURF expression in the heart or skeletal muscle is thus crucial for normal muscular
function.
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2.4.4 Ubiquitination targets and interaction partners of
MURFs
Direct ubiquitination targets of TRIM55 are poorly characterized while there is
more evidence on direct targets of TRIM63. TRIM63 has been shown to
ubiquitinate cardiac troponin I (cTnI) (Kedar et al. 2004; Witt et al. 2005) and 
target it to degradation (Kedar et al. 2004). Witt et al. also showed that both
TRIM55 and TRIM63 interacted, in addition to cTnI, with MLC2, myotilin,
nebulin, NRAP, T-cap and troponin T, but ubiquitination selectively by TRIM63
was only shown for cTnI and MLC2 (Witt et al. 2005). Moreover, TRIM54 and 
TRIM63 have been shown to ubiquitinate and mediate degradation of myosin
heavy chain ˜ (Fielitz et al. 2007a). The signaling protein phospho-c-Jun is another
ubiquitination target of TRIM63 (Li et al. 2011) and signaling of peroxisome
proliferator-activated receptor alpha (PPARα) has been shown to be reduced by
monoubiquitination by TRIM63 (Rodríguez et al. 2015). Ubiquitin-proteasome-
dependent degradation of p62 has been shown to depend on TRIM55, specifically
on its MURF2A isoform (Pizon et al. 2013). PPARα and PPARγ are 
monoubiquitinated by TRIM55 (He et al. 2015). 
2.4.5 Specific role of TRIM55 in the heart
TRIM55 is involved in sarcomere assembly, it colocalizes with tubulin during
myofibrillogenesis, and its functions are partly redundant with TRIM54 (Perera et
al. 2011). TRIM55 has been shown to interact with NBR1, LC3 (Pizon et al. 2013), 
p62 (Lange et al. 2005; Pizon et al. 2013), titin, serum response factor (SRF) (Lange 
et al. 2005), microtubules and myosin (Pizon et al. 2002). In cardiomyocytes, 
TRIM55 has been shown to translocate into the nucleus by cellular stress caused by
starvation (Pizon et al. 2002) or contractile inactivity, which resulted in concomitant
nuclear exclusion of SRF (Lange et al. 2005). Localization of TRIM55 has been
shown to be dependent on tyrosine kinase activity of titin, likely controlled by
mechanical strain (Lange et al. 2005).
While functions of TRIM55 seem to be largely redundant with other MURFs,
there is, however, evidence on its independent significance in cardiac disorders.
Trim55-knockout mice have more severely impaired cardiac function in diabetic
cardiomyopathy, caused by high-fat diet, which is potentially mediated through 
increased PPARα and PPARγ signaling (He et al. 2015). Moreover, in rats with
spontaneously hypertrophic hearts, Trim55 expression is negatively correlated with 
left ventricle mass, and in human idiopathic DCM, TRIM55 expression is reduced
(Prestes et al. 2016). Finally, HCM patients with rare, nonsynonymous mutations in
TRIM55 or TRIM63 are generally younger and their left ventricular wall thickness is
greater compared to the patients without these mutations, suggesting pathogenic, 
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disease-modifying consequences of dysfunctional TRIM55 or TRIM63 (Su et al.
2014). However, a more recent larger study did not report as high excess of TRIM55
or TRIM63 variants among HCM patients as compared to controls (Walsh et al.
2017).
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3 Aims
1) To identify RTKs with potential as novel therapeutic targets for
myocardial ischemia-reperfusion injury using human gene expression
data, a pig model of ischemia-reperfusion, and cardiomyocyte models.
2) To identify novel therapeutic targets for myocardial
reperfusion injury using drug and shRNA libraries.
ischemia-
3) To identify novel genetic markers predicting risk of heart failure in the
FINRISK population and functionally validate candidate variants in 
vitro and in vivo.
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4 Materials and Methods
4.1 Cell culture (I-III)
The cell lines used in the study were HL-1 mouse atrial cardiomyocytes (Claycomb 
et al. 1998) and H9c2 rat cardiomyoblasts (Kimes & Brandt 1976). HL-1 cells were 
grown in Claycomb medium (Sigma), supplemented with 0.1 mM norepinephrine. 
H9c2 cells were grown in Dulbecco’s Modified Eagle Medium. Both media were
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine or 
UltraGlutamine (Lonza) and 50 U/ml of both penicillin and streptomycin (Lonza).
Culture dishes for HL-1 cells were coated with a solution of 10 μg/ml fibronectin 
(R&D Systems) and 0.02% gelatin in distilled water at 37 °C for at least one hour. 
Trypsin inhibitor was used after trypsin-mediated detachment of HL-1 cells.
4.1.1 Hypoxia-reoxygenation treatment (I-II)
Ischemia-reperfusion injury was simulated on cells using hypoxia and
reoxygenation. Cells were exposed to hypoxia (1% O2) in a hypoxic workstation 
(InVivo2, Ruskinn Technology Ltd.) one day after plating for 1 to 48 hours, depeding
on experimental setting and readout. For reoxygenation, cells were restored to
normal cell incubator (21% O2) for 1 to 24 hours before sample collection or
experimental measurements. Samples collected in the end of hypoxic treatment for
Western blotting were lysed while the cells still remained in the hypoxic workstation.
4.1.2 Transient transfection (III)
HL-1 cells were transiently transfected with expression plasmids (described in 4.2)
using Lipofectamine 2000 (Thermo Fisher Scientific) in Opti-MEM (Gibco)
medium 24 hours after plating according to manufacturer’s instructions.
4.1.3 Fluorescence-activated cell sorting (FACS) (III)
Green fluorescent protein (GFP)-positive HL-1 cells transfected with GFP-encoding
plasmids were sorted 24 hours after transfection with SH800 cell sorter (Sony) to 
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enrich transfected cells for downstream experiments. For sorting, cells were diluted
in a solution of 2% FBS and 25 mM HEPES buffer in phosphate buffered saline 
(PBS) and kept at room temperature. Cells were sorted to Claycomb medium
supplemented with 20% FBS.
4.1.4 Generation of HL-1 cell lines carrying Trim55 variants 
with CRISPR-Cas9 (III) 
HL-1 cells carrying mutations in Trim55 gene were generated with clustered
regularly-interspaced-short palindromic repeats (CRISPR)-Cas9 using homology-
directed repair (HDR) method. Single guide RNA (sgRNA) (sequence: 5’-
GGCGCCAAAAACCTTGCACA-3’) targeting Trim55 was cloned in to the
plasmid encoding Cas9 enzyme together with GFP (4.2) using oligo
inserts (5’-CACCGGGCGCCAAAAACCTTGCACA-3’ (top) and 5’-
AAACTGTGCAAGGTTTTTGGCGCCC-3’ (bottom)) according to the protocol by 
Ran et al. (Ran et al. 2013). The plasmid was transfected to HL-1 cells together with 
the HDR template containing the specific coding mutation (TRIM55 E140K) to be
introduced to Trim55 (5’- TTATCTCCTCCCAGGCCAGAAAAAAAATTGGAC
CAGCCCATGTGTGAAGAGCATGAAGAGGAACGCATCAACATCTATTGT 
CTGAACTGTAAAGTGCCCACATGCTCTTTGTGCAAGGTTTTTGGCGCCC 
ATAAGGACTGCCAGGTGGCTCCCCTGACTCATGTGTTCCAGAGGCAGA 
AGG-3’). Two days after transfection, 16,000 GFP-positive cells were sorted to a
24-well plate well using FACS and seven days later, cells were seeded as single cells
to 384-well plate wells. Clones were expanded and genotyped with sequencing
around the mutation site (single alleles of the selected clones cloned into plasmids 
for sequencing each allele separately). One clone with the desired TRIM E140K
variant, in combination with a deletion allele (E140K/–), and additionally, clones
with homozygous (–/–) and heterozygous (WT/–) deletions of Trim55 were used in
the validations.
4.1.5 Ligands, chemical compounds and inhibitors (I-III)
Ligands, chemical compounds and inhibitors used in the study are listed in Table 3.
Concentrations and timing of the treatments are described for each experiment in the
later sections.
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Table 3. Ligands, chemical compounds and inhibitors used in the study
REAGENT APPLICATION VENDOR USED IN
Wnt-5a ROR1 stimulation R&D Systems I
Gefitinib EGFR inhibition Cayman Chemicals II
Afatinib EGFR-ErbB2-ErbB4 inhibition SCBT II
Isoproterenol Hypertrophic stimulus Sigma-Aldrich III
MG132 Proteasome inhibition Sigma-Aldrich III
4.2 Expression plasmids (III)
Expression plasmids described in Table 4 were generated for this study using general
molecular cloning techniques. Site-directed mutagenesis was used to generate the 
mutated TRIM55 E140K plasmids. Generated constructs were confirmed with
sequencing. Mammalian expression plasmids were used to express the proteins in
mammalian cells. Zebrafish expression plasmids were used for expression of the
proteins in zebrafish embryos (see 4.16). References of the background plasmids
used for cloning these constructs are described in III.
Table 4. Expression plasmids generated for this study
INSERT BACKBONE PURPOSE
hSpCas9, GFP, sgRNA pSpCas9(BB)-Cas9-2A-GFP Mammalian expression
GFP-TRIM55 WT pEZYegfp Mammalian expression
GFP-TRIM55 E140K pEZYegfp Mammalian expression
GFP-Luciferase pEZYegfp Mammalian expression
TRIM55 WT, GFP pDESTTol2pA2 Zebrafish expression
TRIM55 E140K, GFP pDESTTol2pA2 Zebrafish expression
GFP pDESTTol2pA2 Zebrafish expression
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4.3 Primary antibodies
Table 5. Primary antibodies used for Western blotting (WB), immunoprecipitation (IP) or
immunofluorescence (IF) experiments. Abbreviations: CST, Cell Signaling Technology;
DSHB, Developmental Studies Hybridoma Bank; SBCT, Santa Cruz Biotechnology; 
Sigma, Sigma-Aldrich;Thermo, Thermo Fisher Scientific; Ubiquitin, poly- and 
monobiquitinated proteins.
ANTIGEN CATALOG
ID OR 
CLONE
VENDOR HOST SPECIES 
AND TYPE
APPLI-
CATION
USED
IN
actin sc-1616 SCBT goat polyclonal WB I
Akt 9272 CST rabbit polyclonal WB I
α-actinin 710947 Thermo rabbit polyclonal IF III
α-tubulin sc-5546 SCBT rabbit polyclonal WB I
cTnI ab209809 Abcam rabbit monoclonal WB III
GAPDH G8795 Sigma mouse monoclonal WB I, III
GFP ab290 Abcam rabbit polyclonal IP III
myosin MF 20 DSHB mouse monoclonal IF III
p21 sc-6246 SCBT mouse monoclonal WB III
p38 9212 CST rabbit polyclonal WB I
p62 23214 CST rabbit monoclonal WB, IP III
phospho-tyrosine 4g10 produced in house mouse monoclonal WB I
phospho-Akt (S473) 4060 CST rabbit monoclonal WB I
phospho-p38 9211 CST rabbit polyclonal WB III
ROR1 sc-83033 SCBT goat polyclonal WB I
ROR1 sc-130386 SCBT goat monoclonal WB, IP I
SRF 5147 CST rabbit monoclonal WB, IP III
TRIM55 PA5-62826 Thermo rabbit polyclonal WB III
TRIM55 ab4387 Abcam goat polyclonal WB III
Ubiquitin FK2 Sigma mouse monoclonal WB III
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4.4 Small interfering RNAs (I, III)
Small interfering RNAs (siRNA) were used in knockdown of the expression of
mouse Ror1, Ror2 (I) or Trim55 (III) in HL-1 cells (Table 6). Lipofectamine 2000
(Thermo Fisher Scientific) was used for siRNA transfections 24 hours after plating. 
The final concentration of siRNAs on the cells was 100 nM. Knockdown efficacy 
was confirmed with Western blotting. All siRNAs were acquired from Qiagen.
Table 6. SiRNAs used in the study
TARGET CATALOG ID USED IN
Ror1 SI01404655 I
Ror1 SI01404662 I
Ror2 SI01404683 I
Ror2 SI01404690 I
Trim55 SI04422859 III
Trim55 SI00972853 III
Trim55 SI00972860 III
NEGATIVE CONTROL SI03650318 I, III
4.5 Cell lysis, immunoprecipitation and Western 
blotting
Cells were lysed for immunoprecipitation and Western blotting, after washing with
PBS, with lysis buffer containing 1% Triton X-100, 10 mM Tris-Cl pH 7.4, 150 mM
NaCl, and 1 mM EDTA. Lysis buffer was supplemented with either separate
protease and phophatase inhibitors (5 mM NaF, 10 μg/ml aprotinin, 10 μg/ml 
leupeptin, 1 mM Na3VO4, 2 mM PMSF, and 10 mM Na4P2O7) or with Pierce
Protease Inhibitor Mini Tablets (Thermo Fisher Scientific). Lysates were centrifuged
for 15 min at 16,000 x g and protein concentration of the recovered supernatants was 
measured with Bradford assay (Bio-Rad).
Immunoprecipitation was performed using 1–2 mg of total protein by incubating
the lysates overnight at +4 °C with target specific antibodies. Subsequently, the
lysates were incubated with Protein G PLUS-Agarose beads (sc-2002, Santa Cruz
Biotechnology) for 60-90 minutes and the beads were washed three times with lysis
buffer. Elution and denaturation of the precipitated proteins was carried out by 
heating the beads in Laemmli buffer at 95 °C for five minutes.
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For Western analyses, lysates were heated at 95 °C for five minutes before
loading to 8-15% polyacrylamide gels. Proteins were separated on the gels with
electrophoresis and transferred to nitrocellulose or polyvinylidene difluoride
membranes. Membranes were blocked with a solution of 5% milk or bovine serum
albumin (BSA) in TBS-T solution (50 mM Tris-HCl (pH 7.6), 150 mM NaCl and
0.05% Tween-20) and incubated overnight with the primary antibodies. After 
incubation of the membranes with horseradish peroxidase (HRP)-conjugated (Santa 
Cruz Biotechnology) or IRDye secondary antibodies (LI-COR)), signals were
detected either with WesternBright ECL (enhanced chemiluminescence) HRP
substrate reagent (Advansta) and imaging with ImageQuant LAS 4000 (GE
Healthcare Life Sciences) for HRP-conjugated secondary antibodies, or imaging 
with Odyssey imaging system (LI-COR) for IRDye antibodies. Densitometric
quantitation of the signals was performed with Fiji/NIH ImageJ v. 2.0.0.
Total protein levels of ROR1 and ROR2 were studied in HL-1 cells and H9c2
cells after hypoxia-reoxygenation treatments (I). Cell lysates were collected after
hypoxic treatment for one, three or 24 hours, and additionally after subsequent
reoxygenation for three or 24 hours and were analyzed by Western blotting. ROR1
phosphorylation in HL-1 cells after one-hour hypoxia, and additionally after 24-hour
reoxygenation, was studied with immunoprecipitation of ROR1 and subsequent
Western blot analysis of tyrosine phosphorylation (I). Moreover, total protein levels
and phosphorylation levels of signaling proteins Akt and p38 were studied in HL-1 
cells after siRNA-mediated knockdown of ROR1 (cell lysates collected 48 hours
after transfection), and after Wnt-5a treatment at 400 ng/ml for 30 or 60 minutes (I).
Lysates were analyzed with Western blotting. Finally, ROR1 total protein levels in
pig myocardium samples (both normoxic and ischemia-reperfusion-injured) were 
studied with direct Western blotting.
Total protein levels of TRIM55, p21, p62, SRF, cTnI and ubiquitinated proteins
were studied in CRISPR-edited HL-1 cell lines carrying Trim55 variants (III).
Lysates were collected three days after plating and analyzed with Western blotting.
Additionally, ubiquitination of SRF and p62 was studied in the edited cell lines with 
immunoprecipitation of the target proteins, followed by Western analysis of poly-
and monoubiquitinated proteins (III). MG132 was used on wild-type HL-1 cells at
50 or 100 μM for 3 or 5 hours before cell lysis to block proteasomal degradation of
ubiquitinated proteins to demonstrate specifity of the anti-ubiquitin antibody (III). 
4.6 Cellular viability assays (I-III)
CellTiter-Glo (CTG) Luminescent Cell Viability Assay (Promega), measuring ATP
content of the cells, and CellTiter 96 Non-Radioactive Cell Proliferation Assay
(MTT), measuring metabolic activity of the cells by assessing reduction activity, 
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Materials and Methods
were used to quantitate viability and proliferation of HL-1 cells. Assays were 
performed on 96-well or 384-well plates according to manufacturer’s instructions. 
Wells containing only growth medium were used for background subtraction.
In the experiments using siRNA-mediated knockdown of ROR1 or ROR2 (I),
HL-1 cells were exposed to hypoxia for 24 hours one day after transfection, followed 
by 24-hour reoxygenation, or grown in normoxia as controls before viability
measurements. To study the effect of Wnt-5a on the viability of HL-1 cells (I), Wnt-
5a was administered to the cells at 200 or 400 ng/ml at the time of plating for 72
hours. The cells were grown in normoxia as controls or exposed to hypoxia one day
after plating for 48 hours, followed by 24-hour reoxygenation before viability
measurements.
Gefitinib, used in chemical validation experiments (II), was administered to HL-
1 cells at the time of plating at concentrations ranging from 1.6 nM to 5 μM. The
following day, the cells were exposed to 24-hour hypoxia treatment, followed by 24-
hour reoxygenation, or were grown in normoxia as controls, before viability
measurement.
Viability of CRISPR-edited HL-1 cells (III) was assessed three days after
plating. TRIM55-transfected cells were let to grow for two days after sorting before 
viability measurements.
4.7 Pig model of myocardial ischemia-reperfusion 
injury (I)
Pig experiments were approved by the Laboratory Animal Care and Use Committee 
of the State Provincial Office of Southern Finland (license number: ESAVI/
1167/04.10.03/2011). Drs. Christopher Stark and Timo Savunen performed the pig
experiments and kindly provided the myocardium samples. Global myocardial
ischemia-reperfusion injury was produced by exposing anesthetized pigs (n = 4) to 
cardiopulmonary bypass with aortic cross-clamping and cardioplegia for one hour,
followed by reperfusion for 29–31 hours in anesthesia, before sacrificing the pigs.
Control pigs (n = 3) underwent similar anesthetic procedures. For anesthesia,
infusion of propofol, midazolam and phentanyl was used and pigs were ventilated
with a respirator. Additionally, pigs were administered cefuroxime as antibiotic
prophylaxis, heparin, enoxaparin, lidocaine, amiodarone, bupivacaine, and 
noradrenaline. In the end of the procedures, myocardial samples were collected from
left ventricles and snap-frozen. Hematoxylin-eosin staining was used for formalin-
fixed, paraffin-embedded tissue samples to study the histological changes of the
myocardium. Ischemic injury was confirmed with troponin T measurement (Elecsys
Troponin T high sensitive, Roche).
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4.8 Phospho-RTK array analysis of pig 
myocardium samples (I)
Pig myocardium samples were analyzed with a phospho-RTK array kit (Proteome
Profiler Human Phospho-RTK Array Kit (R&D Systems)) targeting 49 human 
RTKs. Samples were homogenized and lysed with a lysis buffer provided with the 
kit, and the analysis was performed according to manufacturer’s instructions.
Phosphorylation signals were quantitated with ImageJ software. Phosphorylation 
status of individual RTKs was compared between normoxic controls and ischemia-
reperfusion injury samples.
4.9 RNA extraction, RNA-sequencing and real-time
RT-PCR (I, III)
Total RNA from pig myocardium samples (I), CRISPR-edited HL-1 cell lines (III), 
or zebrafish embryos (III) was extracted with either TRIsure reagent (Bioline),
RNeasy Mini Kit (Qiagen), or with NucleoSpin TriPrep kit (Macherey-Nagel).
Samples were treated with DNase I to reduce genomic DNA carryover.
Genome-wide, strand-specific RNA-sequencing (RNA-seq) of CRISPR-edited 
HL-1 cell lines was performed at FIMM sequencing unit using HiSeq 2500 System
(Illumina) with target coverage of 6 million reads per library (III). Quality control of
the results was performed with Bluebee platform (Lexogen Gmbh). For differential
expression (DE) analysis, raw read counts (excluding genes without more than one
count per million per each replicate in at least one cell line) were analyzed with
DESeq2 package for R. Absence of batch effects between biological replicates was 
confirmed with principal components analysis (PCA). Significantly enriched 
pathways among the differentially-expressed genes were analyzed with gene set
enrichment analysis (GSEA) using fgsea package for R.
For generation of cDNA libraries, 200-1000 ng of total RNA was included in
reverse transcription reaction, using RevertAid First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific) or SensiFAST cDNA Synthesis Kit (Bioline). In real-
time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis of pig
myocardium samples, Universal Probe Library (UPL) probes (Roche) were used in
the reactions with TaqMan Universal Master Mix II (Thermo Fisher Scientific). A 
QuantStudio 12 K Flex Real-Time PCR System thermal cycler (Thermo Fisher
Scientific) was used to carry out the reactions. For HL-1 cell line and zebrafish
embryos samples, reactions were performed with a CFX384 Touch Real-Time PCR
Detection System (Bio-Rad), using iQ SYBR Green Supermix (Bio-Rad) which 
requires no probes as accumulation of PCR products is detected with SYBR Green I
dye. All reactions were performed with technical triplicates per each biological
sample. Used primers and probes are listed in Table 7.
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Materials and Methods
Table 7. Primer and probes used in RT-PCR reactions. Probe numbers refer to UPL catalog
numbers by Roche.
TARGET SPECIES LEFT PRIMER RIGHT PRIMER PROBE USED
IN
Ror1 pig GCGGCTCGCAATATT 
CTC
GAAAGCCCAAGGTCT 
GAAATC
#108 I
Gapdh pig ACAGACAGCCGTGTG 
TTCC
ACCTTCACCATCGTGT 
CTCA
#28 I
Adra2b mouse CAACGAGCTGCTGG 
GCTATT
TGTCCAGACTGATGGC 
ACACA
III
B2m mouse ATTCACCCCCACTGA 
GACTG
TGCTATTTCTTTCTGC 
GTGC
III
Myl7 mouse TGACCCAGGCAGACA 
AGTTC
CGTGGGTGATGATGTA 
GCAG
III
Nppa mouse TTCCTCGTCTTGGCC 
TTTTG
CCTCATCTTCTACCGG 
CATC
III
Trim55 mouse GAAGAGCATGAAGAG 
GAACG
CTATCGTTGCTTCCCA 
CAAG
III
trim55a zebrafish AGCTCATTTGCCCCA 
TTTGCCTTGAG
CGCAGTAGATATTAAT 
CCTCTCGTCCTGATGC 
TCT
III
rpl13a zebrafish GGCGGACCGATTCAA 
TAAGGTTCTGATCATT 
G
CCAGAGATGTTGATAC 
CCTCACACCTCAC
III
TRIM55 human ATCTACAAGCAGGAG 
TCCACCAGGCCAG
TGAGCTCAGACTTCTG 
TCTCTGGAACACA
III
TRIM55 human AGGAGTCCACCAGG 
CCAGAAAAGAAATC
TGGAACACATGAGTGA 
GGGGAGCCA
III
4.10 ShRNA library screening on HL-1 cells (II)
A lentiviral shRNA library, DECIPHER Mouse Module 1 shRNA library (Cellecta)
which targets 4,625 genes with 27,500 barcoded small hairpin RNAs (shRNA), was
transduced to HL-1 cells according to manufacturer’s instructions. Transductions
were performed in triplicates. Half of the transduced populations were exposed to
96-hour hypoxia, which produced visible cellular death, followed by reoxygenation
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for three hours. Half of the cell populations were used as controls grown in normoxia. 
DNA was extracted from the populations, and replicates within treatments were
pooled due to low DNA yield. Barcoded shRNAs were quantitated from the DNA
with next generation sequencing (NGS), performed by Cellecta. Data analysis is 
described in 4.18.
4.11 Drug library screening on HL-1 cells (II)
Drug library screening was purchased from Misvik Biology Inc. (Turku, Finland) as
a service. In the screening, 689 FDA-approved drugs were plated at concentrations
of 40, 200, 1000 or 5000 nM in 384-well plate wells at a density of 1,000 HL-1 cells
/ well. The following day, the plates were moved to hypoxic chamber for 48 hours,
followed by reoxygenation for 24 hours. Control plates were kept in normal cell
incubator for the same time. Cellular viability was measured with the CTG assay. 
Data analysis is described in 4.18.
4.12 Cell cycle analysis (III)
Cell cycle progression of CRISPR-edited HL-1 cell lines or cells transfected with
TRIM55 plasmids was assessed with propidium iodide (PI) staining and flow
cytometry. CRISPR-edited cells were analyzed two days after plating. GFP-positive
transfected cells were sorted with FACS two days after transfection for analysis. 
Cells were trypsinized, pelleted, washed with PBS and rediluted in a solution of 0.1%
Triton X-100 and 3.8 mM sodium citrate. Cells were treated with RNase A for 20
minutes and PI was added subsequently at the final concentration of 50 μg/ml. 
Sample analysis was performed with an Accuri C6 flow cytometer (BD Biosciences)
at the HiLife Flow Cytometry Unit, University of Helsinki. 
4.13 Immunofluorescence microscopy and analysis 
of hypertrophy (III)
Sarcomere structures of CRISPR-edited HL-1 cells were analyzed with
immufluorescence microscopy of α-actinin filaments. Cells were plated on
coverslips and were grown for three days before analysis as described below.
CRISPR-edited HL-1 cells or cells transfected with TRIM55 plasmids were
stimulated with isoproterenol at the concentration of 100 μM for 48 hours to test
their tendency for hypertrophy. Isoproterenol was administered to CRISPR-edited 
cells one day after plating. GFP-positive transfected cells were sorted one day after
transfection and isoproterenol was administered after sorting.
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For immunofluorescence analysis, cells were washed, fixed with 3%
paraformaldehyde, permeabilized with 0.4% Triton X-100 and blocked with 2%
BSA. Incubation with primary antibodies (710947 or MF 20) was carried overnight
at +4 °C. Incubation with the secondary antibodies (Thermo Fisher Scientific) and 
simultaneous counterstaining of the nuclei with Hoechst dye, was performed for 45
minutes. Coverslips were mounted with ProLong Gold Antifade Mountant (Thermo
Fisher Scientific). α-actinin filaments from confocal microscopy images of 135-615 
cells / cell line from two independent experiments were automatically detected and
quantitated using Harmony 4.9 software (PerkinElmer) at the High Content Imaging 
and Analysis (HCA) unit at FIMM.
Hypertrophic response was assessed by measuring cell surface area using
immunofluorescence microscopy after staining with anti-myosin antibody. Cell
surface areas of 282–484 randomly selected cells per treatment from two
independent experiments were manually traced and quantitated with FIJI/ImageJ.
4.14 Calcium transient measurements (III)
CRISPR-edited HL-1 cells plated on coverslips were stained two days after plating
with calcium indicator dye fluo-4 AM (Invitrogen). Cells were kept in Tyrode’s 
solution with 1.8 mM CaCl2 while imaging spontaneous and paced calcium currents
with a fluorescence microscope. Pacing was performed with electrodes generating
bipolar pulses at frequencies of 0.5 and 2 Hz. Calcium transients were quantitated
relative to the background fluorescence using HCImage (Hamamatsu) and Clampfit
(Axon Instruments) softwares.
4.15 Zebrafish embryo experiments (II, III)
Pigment-deficient zebrafish (casper strain) were housed and maintained according
to normal procedures under license MMM/465/712-93 (issued by the Finnish
Ministry of Forestry and Agriculture) at the Zebrafish Core (Turku Bioscience
Centre). Zebrafish embryos were cultured in E3 medium (5 mM NaCl, 0.17 mM
KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) at 28.5 °C. 
In the ischemia-reperfusion model (II), embryos were placed to deoxygenized
water three days after fertilization for 15 or 30 minutes and returned to normal
growth conditions for 24 hours for reoxygenation before readout measurements.
Embryos were treated with gefitinib (500 or 5000 nM) or afatinib (5, 50, 500 or 5000
nM) administered to the water one hour before hypoxic exposure.
To study the effect of trim55a knockout in zebrafish embryos (III), three
trim55a-targeting sgRNAs (Table 8) were injected either separately or pooled 
together into 1–4-cell stage embryos together with recombinant Cas9. Slc45a2-
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targeting sgRNAs were used as negative controls. SgRNAs were synthesized with
SgRNA synthesis kit (New England Biolabs) using the oligonucleotides depicted in 
Table 8. Trim55a knockout efficacy was confirmed with sequencing of the edited
locus, RT-PCR and Western blotting. To address the effect of human TRIM55 WT
or TRIM55 E140K overexpression in the embryos (III), expression plasmids (4.2)
were injected together with in vitro-transcribed Tol2 mRNA into 1–4-cell stage
embryos. Overexpression in the heart was confirmed with fluorescence microscopy
for the GFP control plasmid. Additionally, presence of TRIM55 transgenes in the
genomic DNA was confirmed by PCR and their mRNA expression with RT-PCR.
Fractional shortening or ejection fraction of the heart and heart rate were
measured with videomicroscopy at the end of 24-hour reoxygenation for ischemia-
reperfusion experiments. Measurements were performed four days after fertilization 
for embryos with trim55a knockout or TRIM55 overexpression. Quantifications 
were performed with FIJI/ImageJ.
Table 8. Oligonucleotides used to synthesize the sgRNAs in the zebrafish embryo knockout
model (III)
TARGET SEQUENCE
trim55a TTCTAATACGACTCACTATAGCTCCCCGTGTGGGTAGGTAGGTTTTAGAGC 
TAGA
trim55a TTCTAATACGACTCACTATAGGGCTCTTCACTGGGCTCCGGGTTTTAGAGC 
TAGA
trim55a TTCTAATACGACTCACTATAGCATGTCTGCAGGAGGGACAGGTTTTAGAG 
CTAGA
slc45a2 TTCTAATACGACTCACTATAGGTTTGGGAACCGGTCTGATGTTTTAGAGCT 
AGA
slc45a2 TTCTAATACGACTCACTATAGTTCTCATCGGGATAAAGAGGTTTTAGAGCT 
AGA
4.16 Database analyses (I, III)
A few publicly available databases were used in this study. Messenger RNA
expression levels of 52 RTKs were studied in the Affymetrix expression data from
samples representing healthy heart (n = 62), ischemic cardiomyopathy (n = 63) or
acute myocardial infarction (n = 12), available from IST Online database
(Medisapiens Ltd., ist.medisapiens.com) (I). Expression of the RTKs between
different disease states were compared with Student’s t-test, followed by P-value
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correction with false discovery rate (FDR) method (Benjamini & Hochberg 1995). 
RTK protein sequence conservation between human and pig was addressed by
aligning the RTK amino acid sequences available at UniProt database with EMBOSS
Needle and EMBOSS Water tools by the European Bioinformatics Institute (I) (Rice 
et al. 2000).
Genotype and health status data from the FINRISK study cohort were used for
GWAS of heart failure-associated genetic variants (III). FINRISK is a nationwide
health survey study initiated in 1972 by the Finnish Institute for Health and Welfare,
with new cohorts added every five years (Borodulin et al. 2015). Data from cohorts 
of the years 1992, 1997, 2002 and 2007 were used in this study. After genotype
imputation and removal of data not passing the quality thresholds, 20,118 controls
and 994 heart failure patients were included in the analysis. Association of genetic
variants with heart failure was tested with logistic regression. Tests were corrected
for age, gender, smoking status, hypertension treatment, lipid lowering medications,
diabetes, and 10 first principal components. Coding, functional variants in high
linkage disequilibrium with the lead variants from GWAS were searched for using
PLINK software. Functionality of coding variants was estimated with Variant Effect
Predictor software.
4.17 3D modeling of TRIM55 (III)
3D models of TRIM55 were generated at the Structural Bioinformatics Laboratory, 
Åbo Akademi University. After sequence comparisons between TRIM55 and entries
in the Protein Data Bank, X-ray structures of B-box 2 domain of TRIM63 were used
as templates for modeling the TRIM55 B-box 2 (residues 119-163). Two dimeric
models of TRIM55 B-box 2 were generated with the MODELLER software.
QMEAN software was used to assess the quality of the models and structural
comparisons were performed with VERTAA software. Structural model images
were prepared with PyMOL.
4.18 Statistical analyses
Experimental data in the original publications are presented as barplots (mean as the
bar height and standard error of the mean or standard deviation as error bars); as
boxplots (median, red or black horizontal line; first and third quartile, box; range of
the data, whiskers; and additionally individual values as overlaid dots for some
analyses); as volcano plots; or as dotplots (with median indicated with horizontal
line). Normality of the data was assessed with Shapiro-Wilk test and equality of
variances with Bartlett’s test. Multiple comparisons were performed with one-way 
analysis of variance (ANOVA) (for normally distributed data) or with Kruskall-
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Wallis test (for non-normally distributed data). Two-group comparisons after
multiple comparison tests were performed with two-tailed Student’s t-test (for 
normally distributed data) or with Mann-Whitney U-test or Dunn’s post-hoc test (for 
non-normally distributed data). Multiple testing corrections were performed with 
false discovery rate (FDR) method. Heatmaps and clustering analyses were
generated with heatmap.2 function or pheatmap package for R. Statistical analyses
were performed with RStudio software. RTK expression analyses from IST Online
database (I), DE and GSEA analyses for RNA-seq results (III), and logistic
regression analyses (III) are desribed above.
For quantitation of enriched and depleted shRNAs by hypoxia-reoxygenation in 
the shRNA library screening (II), separate shRNAs targeting the same gene were
used as replicates in the analyses. Differences in abundances of shRNAs were
assessed with three statistical methods (nonparametric quantile regression (Koenker
et al. 2019), DESeq2 (Love et al. 2014) and NBPSeq (Di et al. 2014)). Mean rank of
a gene calculated from ranks from all three methods was used as a measure of
significance for differential expression. Mean rank of 500 was used as a cutoff.
For the analysis of the drug library screening (II), the highest relative
luminescence value of CTG measurements in cells treated with different
concentrations of each drug in hypoxia-reoxygenation was used as a representative
value for each drug. Drugs inducing representative values of one standard deviation
higher than the value for DMSO control-treated cells in the hypoxia-reoxygenation
were considered to significantly increase cellular viability.
Mutual interactions of significant hits from drug and shRNA library screens were
analyzed with protein-protein interaction analysis (II). Protein targets of the drugs
were acquired from the DrugBank database (Wishart et al. 2006). Drugs were
categorized as agonists or antagonists according to information in the Drug Gene
Interaction Database (Cotto et al. 2018). Experimentally validated protein-protein
interactions were acquired using the PSICQUIC package (Shannon 2019). Network 
graphs were generated by applying the protein-protein interactions to the lists of
significantly depleted or enriched shRNAs in hypoxia-reoxygenation, or targets of
antagonist or agonist drugs which significantly improved cell survival in hypoxia-
reoxygenation.
For pathway analysis of significant drug and shRNA targets, all pathway
annotations available at the Molecular Signature Database (Liberzon et al. 2011)
were used. All significant hits from the drug library screening, as described above,
were included. For the shRNA library screening, median normalized counts of
shRNAs targeting the same gene were calculated. Genes with at least 30%
enrichment of the shRNAs (according to median count values in the barcode 
sequencing data) in hypoxia-reoxygenation, compared to normoxic controls, were
included. Maximally collapsing metric learning (MCML) (Globerson & Roweis
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2005; van der Maaten 2009) method was used to calculate the dimensionality-
reduced value for a pathway in control and hypoxia-reoxygenation samples from
median-normalized shRNA counts in the barcode sequencing data or representative
relative luminescence values. Significance score of a pathway was calculated from
the difference between dimensionality-reduced pathway values of control and 
hypoxia-reoxygenation samples. Statistical significances of the pathway significance 
scores and of the fitness of each pathway to the data were calculated by randomly
choosing protein sets with similar length and fitting a probability distribution
function with an Epanechnikov kernel function to the scores of the randomized 
protein sets. P-values were inferred from the cumulative distribution function of the
scores.
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5 Results
5.1 Several RTKs are active and regulated in 
hypoxic heart (I)
RTKs are a potential group of druggable targets for myocardial ischemia-reperfusion 
injury, as they are involved in signaling processes governing cellular survival and
proliferation. Knowledge on RTK activation and regulation in hypoxic or ischemic
heart has been scattered and limited to a relatively small subset of the family
members. Mainly ErbB2 and ErbB4 have been shown to be robustly involved in 
ischemic cardioprotection and cardiac regeneration (Bersell et al. 2009; D’Uva et al.
2015; Wang et al. 2018). We studied the mRNA expression of RTKs in ischemic
human heart in a family-wide screen using the data available from IST Online
database. In acute myocardial infarction, expression of four RTK genes, namely
EGFR, ERBB2, ERBB3 and EPHA2 were found to be downregulated compared to
healthy heart (I, Fig. 1C). As expected, ErbB receptors were among the RTKs
implicated in ischemic injury of the heart.
In our analysis of RTK mRNA expression in hearts with ischemic
cardiomyopathy, several RTKs including EPH receptor genes and ERBB3 were 
downregulated, while ROR1, KIT and TIE1 were upregulated (I, Fig. 1A) when 
compared to healthy heart. Noteworthy, EPHA2 was again downregulated as in acute
ischemia. Interestingly, while ROR1 was the most significantly upregulated gene,
ROR2 expression was downregulated (I, Fig. 1A). Although ROR receptors are
involved in cardiac development, no role for them has been demonstrated in 
myocardial ischemia before.
Phosphorylation of RTKs is a major event in their activation but RTK
phosphorylation in ischemic heart has not been studied systematically at the level of
the whole RTK family. To address this, pig myocardial samples with ischemia-
reperfusion injury were studied with a phospho-RTK array which covers 49 RTKs.
Among the most highly phosphorylated RTKs, EGFR, INSR and several EPH
receptors were included, and additionally e.g. ErbB2 phosphorylation was detected
(I, Fig. 2). Two receptors demonstrated significant differences between controls and
ischemia-reperfusion, as phosphorylation of VEGFR2 was increased and that of
ROR1 was decreased in ischemia-reperfusion (I, Fig. 2A). Our result for VEGFR2 
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are in line with the observation that VEGFR2 is necessary for VEGF-mediated
cardioprotection (Messadi et al. 2014). Interestingly, ROR1 phosphorylation was
downregulated (I, Fig. 2A and 2B), while its mRNA expression was increased in
ischemic cardiomyopathy (I, Fig. 1A). However, in the direct Western blot analysis
of ROR1 protein expression and RT-PCR analysis of ROR1 mRNA expression in
pig myocardium, no significant differences between controls and ischemia-
reperfusion-injured samples were observed (I, Fig. 3).
5.2 ROR1 is downregulated in acutely hypoxic 
heart and its knockdown improves 
cardiomyocyte viability in hypoxia-
reoxygenation (I)
Further characterization of the role of ROR1 in myocardial ischemia was performed
in HL-1 and H9c2 cell lines. A short, one-hour exposure to hypoxia decreased ROR1
total protein levels in both cell lines (I, Fig. 4). In the analysis of ROR1 
phosphorylation with immunoprecipitation and subsequent Western blotting of
phosphotyrosines in HL-1 cells, decreased phosphorylation of ROR1 was detected, 
both after hypoxia for one hour, as well as after one hour hypoxia followed by 
reoxygenation for 24 hours (I, Additional File 6). This observation was concordant
with the decreased ROR1 phosphorylation in pigs after one-hour ischemia and
approximately 30-hour reperfusion period (I, Fig. 2).
To test whether the observed downregulation of ROR1 had functional
significance, viability of HL-1 cells was assessed, both in normoxia and in hypoxia-
reoxygenation setting, after siRNA-mediated knockdown of ROR1. ROR1 
knockdown improved the viability of the cells (I, Fig. 5A), suggesting that the ROR1
downregulation has protective potential. Concordantly, administration of Wnt-5a, a
ligand to ROR1, decreased the viability of the cells (I, Fig. 5C). Phosphorylation of
Akt and p38 was decreased by ROR1 knockdown and increased by Wnt-5a
treatment, suggesting that these intracellular signaling proteins are involved in
mediating the effects of ROR1 signaling (I, Fig. 5B and 5D). The activity of p38 has
been shown to suppress cardiomyocyte proliferation (Engel et al. 2005). Here, it was
not assessed whether the difference in cellular viability was due to differences in
proliferation or cell death. Taken together, however, these findings indicate that
ROR1 signaling suppresses cardiomyocyte viability.
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5.3 Combined shRNA and drug screening reveals
novel potential targets for ischemia-reperfusion 
injury (II)
To search for novel druggable targets for ischemia-reperfusion injury in a high-
throughput setting, genetic screening with an shRNA library, targeting 4,625 genes,
and drug screening with a drug library, consisting of 689 drugs, were performed on
HL-1 cells exposed to hypoxia and reoxygenation. Results were analyzed separately
for both screens using a protein-protein interaction (PPI) analysis among the
significant hits and a pathway analysis to reveal centrally involved signaling
pathways. Both screening methods identified EGFR as the most interconnected node
in the PPI analyses, and in both screenings, EGFR inhibition was found to be
protective for cardiomyocytes (II, Fig. 2A and 2C). EGFR-targeting shRNAs were
enriched by hypoxia-reoxygenation (II, Fig. S1) and EGFR inhibitors gefitinib and
erlotinib enhanced cellular survival in hypoxia-reoxygenation (II, Tables S1 and S2).
Noteworthy, an ACE inhibitor (ramipril) and an ARB (azilsartan) were also detected
as compounds supporting cardiomyocyte survival (II, Tables S1 and S2).
Concordant hits from the two screens were identified as follows: If shRNAs
targeting a gene were significantly enriched in hypoxia-reoxygenation, and if an
antagonist drug targeting the product of the same gene significantly improved 
cellular viability in hypoxia-reoxygenation, the target was regarded as a concordant
hit. Similarly, if shRNAs targeting a gene were significantly depleted in hypoxia-
reoxygenation and a significant improvement in viability with an agonist drug
targeting a product of the same gene was observed, the gene was also regarded as a
concordant finding. Inhibition of the following targets was found out to concordantly
improve cardiomyocyte survival in hypoxia reoxygenation: EGFR, PRKACA
(catalytic subunit α of protein kinase A) and CA2 (carbonic anhydrase 2). Agonism
of the following targets was found out to concordantly improve cardiomyocyte
survival in hypoxia reoxygenation: AR (androgen receptor) and VDR (vitamin D
receptor).
Furthermore, EGFR-related pathways were significantly enriched in the pathway
analyses of both screens (II, Tables 1 and 2). Altogether, both screening methods
suggested EGFR inhibition as cardioprotective in hypoxia-reoxygenation.
5.4 EGFR inhibitor gefitinib preserves cardiac
function in ischemia-reperfusion injury (II)
To validate EGFR as a therapeutic target for ischemia-reperfusion injury, gefitinib 
was chosen as the candidate drug. Gefitinib increased the cellular viability of HL-1 
cells in hypoxia-reoxygenation setting (II, Fig. 3A). To test the activity of gefitinib
in vivo, a zebrafish embryo model of ischemia-reperfusion was used. After 15 
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minutes of ischemic exposure followed by reoxygenation for one day, a significant
decrease in cardiac contractility was observed in control embryos (II, Fig. 3C). 
Administration of gefitinib in the water at concentrations of 0.5 and 5 μM before the
ischemic exposure protected the hearts from the decrease in contractility (II, Fig.
3C). No differences in heart rate were observed. A longer, 30-minute ischemic 
exposure was lethal to a significant fraction of the embryos, and reduction in 
contraction was significantly prevented by gefitinib administered at 5 μM (II, Fig.
S2A). The specificity of the effect of gefitinib and validity of the model was
controlled by using afatinib, an inhibitor of EGFR, ErbB2, and ErbB4, which is
potentially cardiotoxic through ErbB2 inhibition (Nemeth et al. 2017; Schuler et al.
2012). Afatinib administration decreased the cardiac contractility and heart rate in
ischemia-reperfusion at concentrations ranging from 50 to 5000 nM (II, Fig. S2C– 
D). EGFR inhibition with gefitinib was thus validated as a potential mechanism to 
prevent ischemia-reperfusion injury.
5.5 E140K variant of TRIM55 is linked to risk of
heart failure (III)
As heritability of heart failure risk is evident (Lee et al. 2006; Lindgren et al. 2018)
and as the number of identified causative genetic variants is limited (Shah et al. 2020)
we aimed to search for novel genetic variants associated with heart failure in the
FINRISK study population. Logistic regression analysis detected a few variants with 
significant association to heart failure. To identify potential causative variants which 
may affect the heart muscle itself, i.e. coding, damaging mutations in genes highly
expressed in cardiomyocytes, variants in high linkage disequilibrium (LD) with the
variants most significantly associated with heart failure were assessed. This analysis
revealed a variant in the TRIM55 gene, rs138811034 in total LD with an intronic
variant in chromosome 8 (rs117667921), highly associated with heart failure (P = 
2.45 × 10−7) (III, Fig. 1A). Rs138811034 encodes an exonic variant, causing an
amino acid change E140K (glutamate 140 to lysine) in the protein (III, Fig. 1B). This
was predicted to be a likely damaging variant with the Variant Effect predictor
software. Additionally, in silico 3D models indicated that the variant potentially 
affected the surface charge and dimerization of the TRIM55 protein (III, Fig. 1B– 
C). Although the E140K variant was not independently associated with heart failure 
in the cohort, its linkage to the lead variant rs117667921 and its predicted damaging
role warranted further functional validation.
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5.6 TRIM55 E140K affects cardiomyocyte-specific
functions (III)
To functionally validate the role of TRIM55 E140K in cardiomyocytes, HL-1 cells 
carrying the Trim55 variant in the genome were generated using the CRISPR/Cas9
technique. The cell lines used for experimentation included a cell line with a knock-
in of the E140K allele together with a deletion allele (E140K/–), and a homozygous
(–/–) and heterozygous (WT/–) Trim55 knockout cell lines (III, Fig. 2). In whole
transcriptome-RNA-seq analysis, E140K/– cell line clustered together with the –/–
cell line when analyzed according to the most highly differentially expressed genes 
(III, Fig. 3A). Significantly affected pathways in E140K/– cells included pathways
related to muscle contraction and sarcomere structures (III, Fig. 3B). Expression of
Nppa encoding ANP, a typical heart failure and stress marker, was higher in 
E140K/– cells compared to WT/WT cells (III, Fig. 3D). E140K/– cells also
demonstrated reduced viability and impaired cell cycle progression when compared
to wildtype cells (III, Fig. 4A and 4C), and a significant hypertrophic response to
isoproterenol (III, Fig. 4D and 4E). Similarly, the –/– and WT/– cells had a
significant hypertrophic response to isoproterenol, while WT/WT cells did not (III, 
Fig. 4D and 4E).
The effect of the variants on ubiquitination of known TRIM55 target proteins
was assessed with immunoprecipitation and Western blotting. While reduced protein 
levels of SRF and p62 were observed in E140K/– cells (III, Fig. S6A and S6B), their
ubiquitination could not be detected (III, Fig. S6D and S6E). No differences in total
ubiquitination level of the cells were detected, either (III, Fig. S6F). Moreover,
E140K/– cells demonstrated increased expression of cardiac α-actinin (III, Fig. S7A) 
and increased calcium transient amplitudes when paced with 0.5 Hz frequency (III, 
Fig. S7F).
As Trim55 E140K/– cells seemed to have a different phenotype from a total
knockout of Trim55, suggesting a dominant negative effect, activities of the variant
were tested with plasmid overexpression of human TRIM55 in HL-1 cells. TRIM55 
E140K overexpression reduced the cellular viability, compared to WT
overexpression (III, Fig. S8B). Cells overexpressing TRIM55 WT did not have a
significant response to hypertrophic stimulus, while TRIM55 E140K-transfected and
control cells did (III, Fig. S8D and S8E). Thus, while expressed together with
endogenous wild-type TRIM55, TRIM55 E140K produced a different phenotype as 
compared to overexpression TRIM55 WT, supporting the concept of a dominant
negative effect.
To test the effect of the variants in vivo, a zebrafish embryo model was used.
First, knockout of endogenous trim55a gene with CRISPR was shown to reduce
cardiac contractility in embryos four days after fertilization (III, Fig. 5B). Heart-
specific plasmid overexpression was used to specifically test the effect of the E140K
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variant. Both overexpression of E140K variant alone as well as in combination with
TRIM55 WT, mimicking a heterozygous state, reduced cardiac contractility (III, Fig.
5D). Additionally, increase in heart rate was observed in E140K-transfected embryos 
(III, Fig. 5D). 
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6 Discussion
6.1 Novel therapeutic targets for ischemia-
reperfusion are needed
Although many therapeutic approaches to prevent myocardial ischemia-reperfusion 
injury have been assessed, none of them have this far been successfully translated
into clinical practice. One potential reason for the failure of translation is that 
cardiomyocyte death can be triggered via multiple, redundant mechanisms which 
could be acted upon synergistically with multitarget approaches (Davidson et al.
2019; Hausenloy et al. 2017b). In addition to combining the existing cardioprotective
modalities, novel therapeutic targets are needed, as they could provide an additional
mechanism to prevent cellular death (Hausenloy et al. 2017b).
6.2 Novel therapeutic targets for ischemia-
reperfusion can be identified with preclinical
screening approaches
Chemical and genetic screens on cell models are widely used e.g. in cancer research
to identify novel drugs or druggable targets but they have been rarely utilized in the
context of heart diseases. High-throughput drug screening methods on
cardiomyocytes have been used earlier on H9c2 cells to search for cardioprotective
agents against ischemia-reperfusion injury (Guo et al. 2012) and for compounds
protecting from cardiotoxicity of doxorubicin (Gergely et al. 2015). Human iPSC-
derived cardiomyocytes have been used to identify cardiotoxicity of TKIs (Sharma 
et al. 2017). Screening with gene silencing, e.g. with RNA interference or CRISPR 
techniques, is another high-throughput screening method, extensively used e.g. in
cancer research (Diehl et al. 2014; Fredebohm et al. 2013). There are no prior
publications where such methods have been used in heart diseases such as ischemia-
reperfusion injury.
Large-scale preclinical screening methods are an efficient way of identifying
potential molecules taking part in disease pathogenesis. Here, we applied multiple
different screening methods to search for therapeutic targets of myocardial ischemia-
reperfusion. First, the family of RTKs was systematically studied with mRNA
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Discussion
expression data and with a phosphorylation array. Secondly, the drug and shRNA
library screenings were used together to cover thousands of targets. These analyses 
indicated that inhibition of either ROR1 or EGFR could represent novel approaches
to prevent ischemia-reperfusion injury.
6.3 RTK family members are differentially 
regulated by ischemia
Regulation of RTK expression at mRNA or protein level in ischemic heart is poorly 
characterized, although certain RTKs have been studied in more detail, such as
ErbBs (Bersell et al. 2009; D’Uva et al. 2015; Munk et al. 2012; Wang et al. 2018)
and EPHA2 (Dries et al. 2011; O’Neal et al. 2014). Our mRNA expression analysis
of RTKs in ischemic heart indicated downregulation of EGFR, ERBB2, ERBB3 and 
EPHA2 mRNA expression in acute myocardial infarction. For EGFR, this is 
contradictory to the finding by Munk et al. who reported upregulation of EGFR
expression in hypoxic hearts of patients undergoing coronary artery bypass grafting
(Munk et al. 2012). This difference could be due to the fact that the samples analyzed
by Munk et al. were from hearts with chronic ischemia, as compared to acutely
ischemic samples in our analyses. On the other hand, both the results by Munk et al.
and our analyses demonstrated ERBB2 downregulation in ischemic heart, in 
accordance with the observed decrease in ErbB2 protein expression in human
ischemic cardiomyopathy (Gordon et al. 2009). Moreover, EPHA2 expression, along 
with EPHA1, EPHA3 and EPHA7, has been shown to be increased after ischemia-
reperfusion injury in mice (Dries et al. 2011), as opposed to our findings. Altogether,
these discrepancies point to the importance of sampling time after ischemia-
reperfusion injury. The same receptors might undergo different adaptive regulatory
events at different timepoints. Differences between species are also an important
factor to consider.
In the RTK mRNA expression analysis in ischemic cardiomyopathy, both up-
and downregulation of RTK expression was observed. Interestingly, expression was
regulated in opposite directions for ROR1 and ROR2. Expression of ROR1 was
upregulated while expression of ROR2 was downregulated. RTK gene expression
can thus be either upregulated or downregulated in ischemic heart, and it could
reflect either protective responses or pathological adaptations.
Our family-wide screening of RTK phosphorylation in ischemic heart is a
systematic approach that has not been used this context before. Certain aspects of
the screening method should, however, be considered. As the array was designed to
detect human receptors, its functionality on pig samples is debatable. To address this,
we analyzed the similarity of RTK protein sequences between human and pig and
the overall similarity was observed to be high (93.1%). However, direct inferences
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from the observed phosphorylation level or its absence cannot be made with certainty
while the comparisons of levels between control and ischemia-reperfusion samples 
are more reliable. On the other hand, the samples were collected approximately 30
hours afer reperfusion, a timepoint at which the changes in phosphorylation might
already be over. Significantly decreased phosphorylation of ROR1 in ischemia-
reperfusion samples was an intriguing finding as ROR1 expression was the most
significantly upregulated RTK in ischemic cardiomyopathy. These differences could
be due to different disease state (acute vs. chronic ischemia) and the fact that mRNA
expression and phosphorylation are differentially regulated.
6.4 ROR1 inhibition is potentially cardioprotective 
in ischemia-reperfusion injury
The functional role of ROR1 was studied in HL-1 cells. Its knockdown increased the
viability of the cells both in normoxia and hypoxia. Consistently, opposite effects 
were observed upon treatment with Wnt-5a, an activating ligand of ROR1. Wnt-5a
is, however, not an exclusive ligand for ROR1 as it can also activate e.g. ROR2,
RYK and Frizzled receptors (Oishi et al. 2003; Park et al. 2015; Yoshikawa et al.
2003). In accordance with our findings, inhibitors of Wnt-5 and Wnt-3 have been 
shown to reduce infarct size (Laeremans et al. 2011; Yang et al. 2019) and promote
cardiomyocyte proliferation in mice (Yang et al. 2019). These effects are potentially
partly mediated by ROR1. ROR1 inhibition with the targeting antibody
cirmtuzumab, originally developed for the treatment of chronic lymphocytic
leukemia (Choi et al. 2015), is a therapeutic approach worth assessing in the setting
of myocardial ischemia-reperfusion.
Taken together, ROR1 is a key example of an RTK which can exert harmful
effects on ischemic heart. This is an unexpected finding as RTKs are often implicated
in cellular survival and their activity in ischemic heart has previously been reported
to be mainly beneficial. These findings emphasize the multifaceted signaling 
networks RTKs are involved in and that the net effect of a single receptor’s activation
can be either desirable or detrimental for the outcome of the disease. Interestingly,
we observed similarly beneficial effects of inhibiting EGFR activity in
cardiomyocytes, as discussed below.
6.5 Role of EGFR differs from that of ErbB2 and
ErbB4 in the pathophysiology of ischemia-
reperfusion injury
While ErbB2 and ErbB4 are cardioprotective in ischemia-reperfusion injury as
discussed above, the role of EGFR is more complex. Although a lot of evidence
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Discussion
indicates that EGFR transactivation by GPCRs is a necessary event e.g. in ischemic
preconditioning and cardioprotection by multiple compounds (Förster et al. 2007;
Methner et al. 2009; Williams-Pritchard et al. 2011) and that EGF administration
protects ischemic heart (Akhtar et al. 2012; Lorita et al. 2010), contradictory
evidence have shown the benefit of EGFR inhibition in myocardial ischemia (Liu et 
al. 2018; Mali et al. 2018). In our combined screening with an shRNA and a drug
library, EGFR inhibition was one of the concordant hits from both screenings. 
Although ErbB receptors share a number of signaling pathways, the net effect of
EGFR activity can be different from the effect of ErbB2 or ErbB4 activity. This is
also seen in cardiac development, where ErbB2 and ErB4 both affect the
development of cardiac trabeculation (Gassmann et al. 1995; Lee et al. 1995) while 
EGFR is involved in the development of cardiac valves (Chen et al. 2000). 
Speculatively, as EGFR-EGF and ErbB4-NRG-1 signaling axes could use same
coreceptors and signaling cascades, inhibition of EGFR-EGF axis could free the
common downstream mediators to be more available for ErbB4-NRG-1 signaling.
Additionally, EGFR inhibition could potentially cause a reciprocal upregulation in 
expression or activity levels of other ErbB family members which could act in a
cardioprotective manner. As gefitinib is a clinically used cancer drug, it is a suitable
candidate for drug repurposing studies. To this end, further preclinical validations in 
a mammalian model are necessary. As gefitinib was administered here prior to
ischemia, it should be assessed whether the cardioprotective activity also exists if
gefitinib was administered during ischemia or reperfusion. If cardioprotection occurs
only when administered before an ischemic event, it reduces the usability of gefitinib
as an on-demand treatment for acute ischemia-reperfusion injury. In this case,
however, prophylactic use as secondary prevention could be considered.
6.6 Functional characterization of the damaging 
TRIM55 E140K variant gives insight into its
pathological role in heart failure
Cellular functions of TRIM55 have been characterized relatively extensively
(Centner et al. 2001; Lange et al. 2005; Perera et al. 2011; Witt et al. 2005). 
Pathological role of genetic variants of TRIM55 in heart failure has also been
adressed earlier (Su et al. 2014) but their mechanistic characterization has been
lacking. We analyzed the exonic coding variant of TRIM55, encoding E140K variant
in the protein, and detected that it could modify cardiomyocyte-specific functions, 
cellular viability and cell cycle progression in vitro, as well as cardiac contractility
in vivo. Interestingly, the variant was able to exert its effects even in the presence of
a wild-type allele.
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The fact that the variant demonstrated negative effects when expressed together
with the wild-type allele may make the observation more clinically relevant, as most
of the carriers of the variant are heterozygotes. Even though a wildtype allele is
present, E140K variant in TRIM55 could supposedly interfere with sarcomeric
assembly during heart development or with regulation of SRF-mediated
transcription by TRIM55. The identified non-synonymous variants by Su et al. were
regarded to more likely modify the penetrance and disesase severity of HCM, instead
of being independent causal mutations (Su et al. 2014; Walsh et al. 2017). Similarly,
the TRIM55 E140K variant might not be causative on its own but its presence
together with e.g. a sarcomeric mutation could lead to increased susceptibility for
heart failure. Genetic diagnostic methods of heart failure are mostly limited to cases
of suspected or known familial cardiomyopathies when the prevalence of detectable
mutations is high enough (Ponikowski et al. 2016). Increasing knowledge of genetic
variants and cellular functions leading to heart failure is expected to lead to
improvement of treatment modalities. Additionally, preventive measures could be
taken on patients known to carry pathogenic mutations (Czepluch et al. 2018). 
Significance of TRIM55 E140K in heart failure pathogenesis should be confirmed
in larger clinical studies. If it is confirmed to be significant in the clinical setting, it
could be used in genetic screening of cardiomyopathies or heart failure, at least as a
variant modifying the disease susceptibility or severity. Carriers of the variant could
be monitored and treated more rigorously. As one of the findings of the effects of
E140K variant in cardiomyocytes was increased hypertrophic tendency, the
workload of the heart should presumably be kept as low as possible in the carriers of
the variant. This could be done by highly intensive blood pressure lowering treatment
and effective use of ACE inhibitors or ARBs.
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7 Conclusions
Ischemia-reperfusion injury, occurring during myocardial infarction and its
treatment, is an undertreated condition. There are opportunities to enhance outcomes
of myocardial infarction by preventing ischemia-reperfusion injury. New approaches 
to prevent and treat the injury are needed. 
Heart failure is another major factor contributing to heavy burden of heart
diseases. Heritability of heart failure is currently not well known and also presents a
ground for discoveries for better treatment and outcome. 
This thesis work aimed to find novel therapeutic targets for ischemic heart
disease and genetic markers for heart failure using large-scale screening methods to
fill gaps in the knowledge of these fields.
The following conclusions can be made based on the results of the study:
1) ROR1 is a potential druggable target for the treatment of myocardial ischemia-
reperfusion injury.
2) EGFR is a potential druggable target for ischemia-reperfusion injury. The
clinically used EGFR inhibitor, gefitinib, should be assessed further as a
candidate for drug repurposing.
3) Exonic E140K variant of TRIM55 is a potential genetic modifier of heart failure
risk. 
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